Browse Month: March 2017

Aurobindo Pharma Ltd stock quote, Aurobindo Pharma Ltd company overview #url #pharma

#aurobindo pharma


Aurobindo Pharma Ltd (ARBN.NS)

Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Aug 24 Indian shares crept up on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

– Note: Reuters has not verified this story and does not vouch for its accuracy

** Shares of India’s pharmaceutical companies rise, with the Nifty Pharma Index gaining as much as 1.13 pct, its biggest in nearly four months

MUMBAI Aurobindo Pharma Ltd. India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

MUMBAI, May 31 Aurobindo Pharma Ltd, India’s fourth-largest drugmaker by sales, said higher sales in the United States and emerging markets helped its fourth-quarter net profit grow 40 percent, above estimates, sending shares up as much as 4 percent.

** India’s Aurobindo Pharma gains as much as 5.1 pct, highest since Feb. 1, on U.S. FDA approval for its epilepsy prevention drug lacosamide

Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world’s largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on, video, mobile, and interactive television platforms. Learn more about Thomson Reuters products:

Information, analytics and exclusive news on financial markets – delivered in an intuitive desktop and mobile interface

Everything you need to empower your workflow and enhance your enterprise data management

Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks

Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology

The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs

The industry leader for online information for tax, accounting and finance professionals

119 Pharmaceutical Sales Representative Jobs in Dallas, Texas #pharmaceutical #industry #overview #2013

#pharmaceutical companies in dallas tx


Job Search Tips

The ZipRecruiter job matching algorithm analyzes millions of jobs from hundreds of job boards to instantly return the most relevant results. Here are some additional tips to help you optimize your search:

Job titles are best:

Searching for a specific job title provides more accurate results than company names or other keywords. software engineer is better than coder. and registered nurse is better than hospital .

Zip code can help narrow your location:

For location, a zip code is generally more precise than entering city, state.

You can use quotes:

Surround multiple terms in quotes to treat them as a phrase, like: program manager or dental hygenist .

You can exclude certain terms:

Enter a minus sign before any terms you want to exclude, like: -travel or – entry level .

You can require certain terms:

Enter a plus sign before any terms you want to require, like: +full-time or + full benefits .

119 Pharmaceutical Sales Representative Jobs in Dallas, Texas

DSM Pharmaceuticals- Contract manufacturing services #endo #pharma

#dsm pharma


DSM Pharmaceuticals- Contract manufacturing services

DSM Pharmaceuticals, Inc. is one of three business units within the DSM Pharmaceutical Products business group. It is a global provider of finished dosage form manufacturing and related services to the pharmaceutical and biopharmaceutical markets – providing broad capabilities in aseptic filling of liquid and freeze-dried cytotoxic and non-cytotoxic compounds, tablets, capsules, pharmaceutical development services, and clinical trial material manufacturing for solid and injectable forms.

These services are centered at a single, technologically-advanced site in Greenville, North Carolina. The facility offers experience going back to the early 1970s, substantially preceding DSM’s nine-year tenure. This long-term stability and unparalleled expertise, combined with the advanced way the facility is engineered and operated, mean one visit is enough to convince most people that DSM is the ideal partner.

  • DSM Sterile Dosage Forms
  • DSM Sterile Clinical Trial Material Formulation Filling
  • DSM Solid Dosage Forms
  • DSM Premium Quality Systems
  • DSM Pharmaceutical Development Services
  • DSM Cytotoxic Formulation Filling

Aurobindo gets ready to play with the big boys #taro #pharma

#aurobindo pharma


Aurobindo gets ready to play with the big boys

B Dasarath Reddy | Hyderabad Jul 25, 2016 12:39 AM IST

Hyderabad-based Aurobindo Pharmaceuticals is planning to raise funds via a share sale to fund the acquisition of Israel-based Teva Pharmaceutical s European assets, if its bid is accepted by this month.

The company is in a race with two other multinationals for the acquisition. Good profits and a near-doubling of its market value has given the company a confidence booster for the acquisition. Which could cost it as much as $1.3 billion (Rs 8,700 crore). For the promoters of Aurobindo, it might become a bit difficult to keep their characteristic low profile intact towards the end of this month if they win the race. To prepare the ground, the board of directors had cleared its proposal to raise $600 million (Rs 4,000 crore), to fund growth and also use a portion of it for retiring some debt.

Till date, Aurobindo was happy with small-sized acquisitions. The value of its largest one so far was $132.5 mn, an auction sale of US-based nutraceutical Natrol, a year before.

In January 2014, it had paid 30 million (Rs 250 crore) for the loss-making commercial operations in seven western European countries from Irish pharma company Actavis Plc. It was able to quickly this entity around, creating the conditions to think of a big deal. The Actavis step had put Aurobindo among the top 10 in Europe it acquired personnel, commercial infrastructure, products, marketing authorisation and dossier licence rights in seven countries. Both have also entered into long-term commercial and supply arrangements. Europe is the second biggest market for Aurobindo, accounting for 28 per cent of its global formulations business.

Teva Pharmaceutical Industries offer to divest overlapping assets in the UK, Ireland and Iceland a precondition for acquisition of Allergan Plc s generics business, put by the European authorities comes as Aurobindo s oral solid finished dosage facility at Naidupet in Andhra Pradesh was getting ready for commissioning. The facility was being exclusively set up to make products acquired from Actavis, as the company seeks to shift the manufacturing to the lower cost Indian base.

The company might see an upside of Rs 500 crore in top line once the Naidupet facility begins operations in the next three-four months, sources said. On top of the business anticipated from this facility, the spare capacity here and at other units are another reason to bid for Teva s products.

Aurobindo last year said it was spending Rs 900 crore on capacity addition it plans to make India a key sourcing hub for its western European generics drug business. Besides at Naidupet, the company is setting up a finished dosage facility for European markets at Visakhapatnam in Andhra.

There are five-six contenders in the fray. By the end of this month, we might get to know which way the deal would go, a top company official told Business Standard, on condition of anonymity.

P V Ramaprasad Reddy and wife P Suneela Rani together hold 70 per cent of the promoter s and promoter group s share-holding in the company. Currently Aurobindo is the fourth-largest Indian generic pharmaceutical company.

Aurobindo and Lupin are two companies where promoters provide direction and guidance, while letting professional managers run company affairs, a senior industry professional said about Reddy, who is also known for a reluctance to come on a public dais. He was executive chairman till December 2012. Then, he reduced his position to non-executive director, after shifting base to the US, to focus on the growth of Aurobindo s US business.

Aurobindo Pharma has scripted an impressive turnaround post end-FY12, underpinned by its superior execution. The company has stayed compliant with US (regulator s) evolving norms, overcome constraints of a basic generics portfolio and grown FY12-16 US sales at a 40 per cent compounded annula rate (CAGR) to $940m in FY16, went a report issued on Saturday by IDFC Securities.

The key growth drivers are sustained momentum in US sales and turnaround in Europe operations, with reduction in capex intensity from FY18. We anticipate an impressive 20 per cent earnings CAGR and Rs 15 billion free cash generation over FY16-18E, went a report issued on Saturday by IDFC Securities.


  • Teva s offer to sell products in Europe comes in handy for Aurobindo Pharma to pursue an aggressive growth strategy
  • Company is already creating capacities targeting the European market, thanks to the Actavis product portfolio
  • Aurobindo became fourth largest Indian generic drugmaker beating some of the big companies in terms of new launches
  • Company sets itself a $3 bn revenue target by 2017-18, from around $ 2 bn in FY16
  • Teva s product deal is estimated at 1.3 bn at the lower end, little over 50 per cent of Aurobindo s revenues in 2015-16

(With inputs from Dev Chatterjee)

Jobs in pharma #pharma #mba

#jobs in pharma


278BioTech / Pharmaceuticalindustry jobs

  • West
  • Login to view salary
  • Responsibilities: Provide support for finance activities: closing, balance sheet. Responsible to maintain and reconcile general ledger. Review and perform monthly amortization of prepayment on monthly basis prior to month-end close. Assist in preparation of statutory and taxation schedules and.

Associate Engineer (MNC / Pharmaceutical / East / 5D / Up $3.5k / GMP / Gxp Doc / )

  • East (Singapore)
  • Login to view salary
  • Our Clients A fast growing and leading pharmaceutical company of high establishment is undergoing expansion plans in the region to support the.
  • West
  • Login to view salary
  • Responsibilities: Carry out analytical testing on Finished Products and Raw Materials to support production activities, and the needs of other departments/sections such as A TG, Material Management, Procurement, and E M and to ensure timely release of FP and RM. Investigates and documents.

Engineer, Automation

  • Global healthcare leader that offers career growth opportunities
  • Positive and collaborative work environment
  • A shared purpose in saving and improving lives around the world
  • West
  • Login to view salary
  • Under the supervision of the IPT Automation Lead, Automation Engineer is responsible for providing technical support in the field of automation.

Medical Officer

  • West
  • Login to view salary
  • Job Summary Perform Medical Monitoring (Assess feasibility, give scientific input from start up through to close out, review protocols). Maintain.

Medical Sales Executive

  • East
  • Login to view salary
  • Responsibilities Promoting and selling Traditional Chinese Medicine (TCM) products to Chinese medicine clinics and medical halls. Contact new or.

Sr Software Engineer (Bioinformatics) – (5846BR)

  • Singapore – Singapore
  • Do you want to make a difference? Illumina’s mission is to improve human health by unlocking the power of the genome. If that inspires you, let’s.

Organizational Learning Executive

  • West
  • Login to view salary
  • Responsibilities: Address training needs (functional skills and development training) Conduct Annual Training Needs Analysis with business partner to determine departmental training requirements to meet business needs. Monitor departmental training status with individual leaders on regular basis.
  • West
  • Login to view salary
  • Responsibilities: Perform studies to identify and improve existing process efficiency. Conduct process validation in coordination with Technical Services, QA, E M and other departments. Monitor and report indicator of process performance. To lead in motivating and reinforcing expected.

Facility Security Maintenance Specialist – MNC (Medical) / North / S$2.5K to $3.1K

  • North
  • Login to view salary
  • US MNC (Medical) / North/Up to S$3.1K
    Familiar with preventive and corrective maintenance for all Security systems -CCTV, Card Access System, Door Alarm System, and etc
    12 month renewable contract
    Experience in Manufacturing Industry preferred
    Our client.

Senior / Automation Engineer – Life Science MNC

  • East
  • Login to view salary
  • Strong hands-on experience in equipment, Jigs Fixture Factory automation and medical equipment design experience preferred.
    Opportunity to be stationed in US Plant (6- 18 months) for product transfer training
    Singaporean only
    Our client, a US Life Science.

Quality Engineer-Software Validation (US Biomedical Manufacturing)

  • East
  • Login to view salary
  • Responsibilities: Responsible to assure that manufacturing processes comply with the product specification and regulatory government agencies requirements. Provide mechanisms for controlling the total quality and establish ways of evaluating the quality of our products. Responsible to develop.

Pharma & Healthcare #vital #pharma

#pharma supply


Pharma Healthcare

Protect your pharma supply chain

From the point of manufacture to the pharmacy, Zetes’ supply chain solutions help you

  • combat counterfeiting
  • comply with identification, data-aggregation and traceability regulations
  • secure your distribution channels: achieve tight delivery times; trace and fight theft, derivation, parallel market
  • Ensure swift problem resolution of claims and recalls

Maximise performance security on your packaging line

  • Enable high speed marking and labelling (up to 500 packs per minute) in line with stringent industry requirements
  • Establish a full chain of custody, with data-aggregation from package to pallet
  • Enable track trace, using serialisation if needed

Prepare orders fast, ensure logistics traceability

  • Achieve shorter delivery times with fast and efficient order picking
  • Ensure full traceability across warehouse operations, whilst maximising productivity and agility to manage very short delivery times
  • Enable last-minute order fulfilment throughout the day

Deliver on time in full, every time

  • Achieve short delivery windows, enable last minute pick-ups and deliveries
  • Comply with relevant legislation and regulations (track trace, temperature control, …)
  • Track and manage returnable assets

End-to-end traceability across your supply chain

  • Track any object to any level, track any business event at any stage
  • Aggregate data from different sources of information in one unified data-repository
  • Share information in a collaborative way with all stakeholders

Leading companies are optimising their pharmaceutical supply chain with us

1st BME Global Pharma Supply Chain Congress in Frankfurt #world #pharma #news

#pharma supply


1st BME Global Pharma Supply Chain Congress in Frankfurt/Main

The forum takes place from 22nd to 25th February 2016. Main theme at the Frankfurt Marriott Hotel is “Innovative patient-centric supply chain models to improve access to medicines worldwide“.

The BME’s pharma supply chain networking forum takes place in February. Foto: Dr. Klaus-Uwe Gerhardt /

Global Supply Chain Leaders of the world’s most important pharma companies will gather on the 1st BME Global Pharma Supply Chain Congress. Europe’s pioneering pharma supply chain networking forum takes place at the Frankfurt Marriott Hotel from 22 nd to 25 th February 2016 under the main theme Innovative patient-centric supply chain models to improve access to medicines worldwide .

The program includes some of today’s hottest supply chain topics, such as:
  • Leading edge supply chain practices, e.g. end-to-end supply chain integration, market segmentation strategies horizontal and vertical collaboration
  • Distribution excellence as a key driver for commercial success
  • How supply chain can add true value for the patients and contribute to top-line growth

In addition, the congress has a special focus on “Global Health” and the crucial role of pharma supply chain in securing access to medicines for patients worldwide. With tangible global health initiatives that will be discussed on this congress, pharma companies are showing that they are ready and willing to assume their responsibility for the well-being of humanity.

Congress host is the BME, Europe’s leading non-profit industry association for supply chain management, purchasing and logistics.

Snapshot of participating pharma companies to date: AstraZenca, Baxter, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Ferring, Lilly, MSD Sharp Dohme, Merck KGaA, Novo Nordisk, Pfizer, Sandoz, Teva, UCB, Queisser Pharma.

“With more than 60% of the industry participants owning an SVP, VP or Head of job title, this congress provides the perfect opportunity for global pharma supply chain top executives to enjoy a high-quality peer-to-peer networking with other key industry leaders”, stressed Dr. Christoph Feldmann. CEO of BME in Frankfurt.

What else makes this event unique?
  • From the industry for the industry. The congress has been designed by 16 global supply chain leaders deriving from the world’s best pharma companies.
  • Multi-stakeholder approach: Holistic view on pharma supply chain management includes all internal and external key stakeholders.
  • Cross-industry stimulation: Speakers and experts from best-in-class industries share their supply chain best practices and case studies.
  • Outstanding social program: Field trips, pre-evening reception, networking dinner and “grow-your-talent” tables will make it an unforgettable experience.

All confirmed speakers to date rank among the topleading supply chain executives and global health experts:

  • Dr. Ulrich Glas. Corporate SVP Supply Network Lifecycle Management, Boehringer Ingelheim
  • Susanne Hundsbæk-Pedersen. SVP Devices Supply Chain Management, Novo Nordisk
  • Christopher Game. Chief Procurement and Supply Chain Officer, The Global Fund
  • Sheila Tlou. Director UNAIDS former Health Minister of Botswana
  • Cheryl Dhillon. SVP Supply Chain Corporate Project Management, Otsuka Pharmaceuticals
  • Alessandro de Luca. SVP Global Supply Network Operations, Merck
  • Hans Ehm. Head of Supply Chain Innovations, Infineon
  • Dessislava Dimitrova. Associate Director Healthcare, World Economic Forum
Premium Partner Camelot

Camelot Management Consultants, one of the leading strategy consultancies for integrated value chain management, is the exclusive knowledge partner for this event. “The changes in the product portfolio of research-based pharmaceutical industry make traditional supply chain models become a phase-out model. Integrated end-to-end-strategies with wider patient-centric structures along the entire value added chain are in demand”, stressed Dr. Josef Packowski. CEO of Camelot Management Consultants and premium partner of the 1st BME Global Pharma Supply Chain Congress in Frankfurt.

Partner Country Portugal

Portugal is the partner country for the 1st BME Global Pharma Supply Chain Congress. and the BME is proud to announce the Portuguese Health Minister Fernando Leal da Costa as one of the keynote speakers. The country itself is widely recognized as a high‐quality supplier of healthcare products and services, meeting the highest quality standards regarding the development, manufacturing, and supply of Pharmaceutical products. Located on the West Coast of Europe, Portugal is also a privileged European logistics platform due to its closeness to Africa and the Americas.

We will be delighted to welcome you as a press representative at the 1st BME Global Pharma Supply Chain Congress and we look forward to meeting you in Frankfurt.

For more information:

Heike Wittig, Project Lead
Head of Supply Chain Logistics, BME e.V.
Email: heike.wittig(at)

Press Contact/Interview Requests:

Biotechnology – Pharmaceutical #kiadis #pharma

#pharma biotech jobs


You are here

Biotechnology Pharmaceutical

Selected Resources

The resources below are a combination of general industry information as well as specific job and internship posting sites for this industry.

  • . Searches over 150 job sites to pull together listings in biotech and bioinformatics. It also provides company profiles, a knowledge center and articles.
  • Biomedical . Search opportunities by keyword and employer.
  • BioPharmaLink . Lists of organizations by organizational type and product/technology type.
  • . A source of daily biotech and pharmaceutical news, company profiles, jobs, biotech jobs listings.
  • Drug Information Association . Lists industry internships and clinical-development jobs.
  • hireBio . Offers pharmaceutical and biotechnology career information, job postings, industry news and research.
  • hireRx . Lists opportunities by region and specialty.
  • LifeSciencesWorld . International links covering the fields of biotechnologies including the latest biotechnology news and job vacancies. Information is provided on free biotechnology publications and upcoming events and conferences.
  • MedZilla . Listings in biotechnology, pharmaceuticals, health care and science.
  • New Scientist . Features some of the latest science hot topics as well as a job and careers section.
  • Pharmaceutical Manufacturers of America (PhRMA) . Members are approximately 100 U.S. companies that have a primary commitment to pharmaceutical research. Check employment listings. Good source of information on industry statistics, policies, developments and players.
  • Science Magazine . Features jobs, employer profiles and links, and other resources such as the salary calculator.
  • . Guide to Careers in Biotech and Pharmaceuticals.

Selected Professional Associations

A professional association is an organization of people who have similar career interests. These membership- based organizations often offer a reduced rate for students that allow access to the many resources they provide. Professional association websites can also offer job/internship databases as well as opportunities to find mentors or other contacts.

  • Advanced Medical Technology Association (AdvaMed) . Provides professional development, education, advocacy and publications. The job board is fee-based.
  • American Inst. for Medical Biological Engineering (AIMBE) . Founded to establish a clear and comprehensive identity for the field of medical and biological engineering.
  • Biotechnology Industry Organization (BIO) . Professional development, news and updates, plus downloadable guides to biotech careers useful to entry-level job seekers.
  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) . Represents the research-based pharmaceutical, biotech and vaccine sectors.
  • Institute of Biological Engineering(IBE) . Provides industry news and career resources among others and also coordinates student chapters.
  • National Science Foundation (NSF) . An independent federal agency created “to promote the progress of science; to advance the national health, prosperity, and welfare; to secure the national defense…”


Use the dropdown menu to explore more industries.

Pharma Supply Chain #ferring #pharma

#pharma supply


POBOS™ Supply Chain measures end-to-end supply chain performance from supplier to wholesaler. Benchmarked dimensions include service, capital, cost, and capabilities. Ensures apple-to-apple comparison by detailed validation of metrics and definitions, and normalization of key performance metrics based on structural factors. The database covers 20 participants.

Data collection effort:

At company and country/site level

Estimated 3-4 days of time from SCM and Finance



  • What is POBOS
  • How POBOS can help
  • Contact POBOS
  • About McKinsey Co.

URL Pharma: Latest News – Videos, Photos about URL Pharma #dream #pharma

#url pharma



Mere viewing of blocked URLs or torrent website will not attract fine: Experts

The news kicked up an online storm because of the suggestion that merely “viewing” a blocked URL or torrent website could lead to a fine of up to Rs 3 lakh or a jail terms.

23 Aug, 2016, 05.30AM IST

Pharma headwinds here to stay, tread with caution

Seven pharma cos’ managements say pricing pressure and tightening regulatory noose worrisom.

1 Sep, 2016, 08.22AM IST

IT, pharma ultimately going to perform: Rakesh Jhunjhunwala

In IT and pharma, the first few names remain the same, but the order keeps changi.

30 Aug, 2016, 12.25PM IST

Pharma companies in race to acquire Zincovit, Zincofer

Leading pharma players Cadila Healthcare, Torrent Pharma and GSK Pharma are in a three-way race to acquire top-selling zinc-based multi-vitamin brand owned by Chennai based Apex Labs.

29 Aug, 2016, 05.13PM IST

Buy Escorts and Sun Pharma: Experts

As the markets closed past week on the high, coming week is expected to perform better than the last. Experts suggest the stocks that can make news and earn investors good money in trade.

13 Aug, 2016, 01.53PM IST

Buy Escorts and Sun Pharma: Experts

As the markets closed past week on the high, coming week is expected to perform better than the last. Experts suggest the stocks that can make news and earn investors good money in trade.

13 Aug, 2016, 12.48PM IST

Stocks in news: Bharti Airtel, Sun Pharma

The Indian market is expected to open higher tracking positive trend seen in other Asian markets.

18 Aug, 2016, 08.59AM IST

India will be world power in pharma, says Jhunjhunwala; is it time to buy?

Jhunjhunwala continues to bet on the pharma sector and Aurobindo Pharma is his preferred pick, which has rallied a little over 6 per cent in last one year.

31 Aug, 2016, 10.16AM IST

Pharma cos offer freebies to doctors, violate code: MP

The CAG, in a report in 2015, criticised the Central Board of Direct Taxes for allowing promotional expenses by pharma companies as deductible expenses while calculating tax.

30 Aug, 2016, 05.04AM IST

Cadila, Torrent Pharma, GSK in race for top-selling multivitamin brand

Apex Labs pioneered the introduction of zinc-based formulations in the Indian market and the company’s flagship brand Zincovit is the brand leader in its segment with a 19% market share, according to the company website.

29 Aug, 2016, 04.06PM IST

All about stocks: SBI and Sun Pharma

After closing on the highs, markets are expected to open and perform better in the coming week. Watch this video to know the stocks that are expected to give good returns and prove to be safe bet for retail investors.

13 Aug, 2016, 09.19AM IST

USFDA issues warning letter to ex-Sun Pharma US facility

The Philadelphia plant is among the two facilities that Sun Pharma had sold to Frontida BioPharm in June this year, along with 15 products, for an undisclosed amount.

26 Aug, 2016, 06.25PM IST

Buy Aurobindo Pharma Ltd. target Rs 1170.0. Citigroup

The sharp reduction in net debt during the quarter was encouraging and Aurobindo Pharma remained Citigroup’s top pick in Indian pharma space.

25 Aug, 2016, 01.37PM IST

Torrent, Natco, Sun are top pharma picks: Nischal Maheshwari, Edelweiss Securities

One cannot be positive on the whole pharma sector. One has to be very, very stock specific

25 Aug, 2016, 09.54AM IST

With an aim of expansion, pharma companies like Lupin and Torrent eyeing overseas acquisition

They are scouting for niche manufacturing sites, promising experimental drugs, specialty firms in emerging markets and opportunities in the US, Europe or Japan.

25 Aug, 2016, 02.24AM IST

#LeanIn: Maternity Bill passed in RS, now women to get 6 months off

While India was rooting for PV Sindhu, Andhra Pradesh and Telangana were googling her caste

The wait is over: iPhone 7 is coming soon

Centre returns bill for 400 per cent hike in Delhi MLA salaries

Price war: Idea, Vodafone and Bharti Airtel to slash tariffs to compete with Reliance Jio

Can football help you build your portfolio?

‘No chance’ of returning to the family business, says Onida Group’s Sasha Mirchandani

Best 13-inch laptops of the year

How to permanently erase data from an Android device

An IAS officer got a call from PM Narendra Modi at 10 PM and this is what happened next

Smartphones which are compatiable with Reliance Jio

Kolkata will take a century to recover from Mother Teresa

Reliance Jio data plan tariffs: All you want to know

Cyclical mutual funds: Running the relay of business cycles profitably

I spent my first salary on candies: Sunny Leone

5 smartphones likely to launch this week

US immigration debacle over, SRK takes selfies with fans at son’s film school

Air India Express turns profitable for the first time


Barrett, et al, v #biotech #pharma

#forest pharma



Case Type: Gender Pay, Promotion and Pregnancy Discrimination Class Action
Company: Forest Pharmaceuticals, Inc.; Forest Laboratories, Inc.

Barrett, et al, v. Forest Laboratories, Inc. et al.

In July 2012, Sanford Heisler, LLP filed a $100 million class action lawsuit against Forest Laboratories, Inc. and Forest Pharmaceuticals, Inc. (“Forest”) in federal court in New York, alleging, among other claims, that Forest discriminates against its female Sales Representatives by paying them less than their male counterparts. The Plaintiffs also allege claims of failure to promote, discrimination based on pregnancy and maternity leave, sexual harassment, and retaliation. In 2014, the Court denied Forest’s attempt to dismiss the Plaintiffs’ claims, and in 2015 the Court conditionally certified a class under the Equal Pay Act (EPA).

Plaintiffs’ Equal Pay Act Claims

The EPA requires that men and women in the same workplace be given equal pay for equal work. A female Forest Sales Representative who believes that she was paid less than men who performed similar work may be eligible to join this lawsuit, which seeks to recover wages that we allege Forest wrongfully denied female Sales Representatives.

In September 2015, the Court conditionally certified Plaintiffs’ EPA claims to proceed as a “collective action,” holding that Plaintiffs had shown sufficient evidence that female Sales Representatives at Forest were paid less than their male counterparts for the same work. The Court ordered notices to be distributed to approximately 2,000 current and former Forest Sales Representatives who may be eligible to join our lawsuit.

Click here to view the full Court-ordered notice.

Federal law prohibits any employer from taking any action against you because you express interest in or elect to join this collective action, or for providing information relevant to this lawsuit that may support the Plaintiffs’ claims. Attorneys from Sanford Heisler, LLP are on call to ensure that these rights are protected.

If you have any questions about the lawsuit, please contact Plaintiffs’ Counsel, Sanford Heisler, LLP by phone at (646) 402 -5650.

More information on the other claims alleged in this case can be found here.

Forest Laboratories to Acquire Furiex Pharmaceuticals #orchid #pharma

#forrest pharma


Forest Laboratories to Acquire Furiex Pharmaceuticals

Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion.

Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon successful completion of Forest’s acquisition of Furiex.

“The acquisition of Furiex builds on our growing position in gastroenterology and helps to create a leading GI company within Forest. It is a natural extension of our GI business following our $2.9 billion acquisition of Aptalis earlier this year,” said Forest’s Chief Executive Officer and President Brent Saunders. “We believe eluxadoline will be very complementary to our anchor GI product Linzess and additive to our broader GI portfolio, making us more relevant to gastroenterologists and primary care physicians. With eluxadoline, we expect to have one of the broadest product offerings for the $38 billion GI disease market.”

Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist and a delta opioid receptor antagonist for treating symptoms of diarrhea-predominant IBS (IBS-d). Furiex is on track to submit a New Drug Application (NDA) for eluxadoline to the US Food and Drug Administration (FDA) by the end of the third quarter of 2014. The drug was granted fast-track status by the FDA.

In February, Forest Laboratories announced that it has entered into an agreement with Actavis, under which Actavis will acquire the company for $25 billion. According to Forest, the acquisition of Furiex will not affect the timing of Actavis’ takeover and Actavis agreed to the Furiex acquisition bid and supports it. Earlier this year, Forest completed a $2.9 billion acquisition of Aptalis, which makes gastrointestinal and cystic fibrosis treatments.

“In partnering on this transaction, we believe Forest and Royalty Pharma have created a win-win situation,” said Royalty Pharma’s Chief Executive Officer Pablo Legorreta. “Forest will acquire a company with a very exciting GI product candidate, while Royalty Pharma will acquire the non-core passive royalty assets. Our goal is to become the M A partner of choice for pharma and biotech companies, allowing them to focus their resources on strategic assets.”

Forest said that it expects the acquisition of Furiex to close in the second or third quarter of 2014, following regulatory review and Furiex shareholder approval.

Source: Forest Laboratories Inc.

Last updated: 4/28/14; 2:25pm EST

As Pharma Jobs Leave N #global #pharmaceutical #companies



As Pharma Jobs Leave N.J. Office Space Ghost Towns Remain

Tom Stanton of the real estate firm Jones Lang LaSalle shows off empty lab space at Roche in Nutley, N.J.

New Jersey used to be known as “the nation’s medicine chest,” but over the past two decades, many of the state’s pharmaceutical industry jobs have dried up or moved elsewhere, and left millions of square feet of office space, warehouses and laboratories sitting empty.

One of those sites is the 116-acre corporate campus of the Swiss drugmaker Roche in Nutley, N.J. There are dozens of buildings on this campus, 10 miles west of midtown Manhattan. In fact, there are enough bio and chem labs, offices and auditoriums to fill up the entire Empire State Building. But since December, all of that space — 2 million square feet of it — has been vacant, the laboratories dark and the sidewalks deserted.

“When this was a thriving site, this sidewalk would have been busy with folks walking up and down,” says Darien Wilson, one of just 38 Roche employees still working at the site as the company tries to sell the property. “We had great amenities for people, like on-site child care. You had dinners to-go where you could order food by lunch and take it home with you if you were working late. We had dry cleaning,” she says.

Five years ago, Roche acquired Genentech, moved its management to San Francisco and started to slowly withdraw from New Jersey. That’s a pretty typical story for what’s been happening in the state. In the past 20 years, New Jersey went from having more than 20 percent of U.S. pharma manufacturing jobs to less than 10 percent.

“Essentially, every time there’s a merger or one company acquires another company, there’s a reduction in force, and there’s been furious mergers and acquisitions in the pharma industry, particularly over the past 10 years,” says James Hughes, dean of the school of public policy at Rutgers.

A Roche lab in 2009, a more bustling time. Mel Evans/APhide caption

toggle caption Mel Evans/AP

A Roche lab in 2009, a more bustling time.

In 2009, Merck bought Schering-Plough, and Pfizer bought Wyeth. This year Pfizer tried to purchase the British drugmaker AstraZeneca. And the list goes on.

Business professor Erik Gordon of the University of Michigan says cutting-edge research isn’t being done on closed campuses in the suburbs anymore.

“The new innovation in biotech, in genomics is happening elsewhere. It’s happening in places where there are graduate educational institutions that have research faculty doing that, and New Jersey really doesn’t have that,” he says.

That’s something Roche is acutely aware of as it looks for a buyer.

“What really sets this site apart is its location,” says Tom Stanton of Jones Lang LaSalle, the real estate firm marketing the site.

The site is so big that to show it off, Stanton needs a minibus. Looping through a parking lot with thousands of empty spaces, Stanton stresses how close the campus is to Manhattan, Newark’s airport and public transit.

“Hiring young, talented people is really important to these companies. And that population of upcoming talent is more into the city life,” he says.

But even though it’s only a good bike ride from Manhattan in a straight line, the Roche campus can feel far away from the city’s pulse. Stanton says finding even a single tenant has been difficult. So far, he’s shown the campus to 35 companies, and no deal yet.

Related NPR Stories

The situation may be even worse for the Merck World Headquarters in Whitehouse Station, N.J. It’s about 50 miles from Manhattan — making its 1 million square feet of space harder to fill.

But there may be an answer. The state’s biotech firms are growing fast, and they may be future tenants for these big pharma campuses. But so far, they’ve only been leasing small portions of space. Stanton says that could work for something like Roche’s Building 123, a six-story structure with a lot of lab space.

“That building [would] cost $600 million to re-create today,” he says.

Young companies would love to get some of its lab space. But they don’t need, and can’t afford, the whole building. Stanton just has to find a way to carve it up and then get some companies to bite.

More Stories From NPR

We no longer support commenting on stories, but you can find us every day on Facebook. Twitter. email. and many other platforms. Learn more or contact us .

URL Pharma – latest news, breaking stories and comment – The Independent #pharmaceutical #recruitment #agencies

#url pharma


URL Pharma

We’ve noticed that you are using an ad blocker.

Advertising helps fund our journalism and keep it truly independent. It helps to build our international editorial team, from war correspondents to investigative reporters, commentators to critics.

Click here to view instructions on how to disable your ad blocker, and help us to keep providing you with free-thinking journalism – for free.

Thank you for your support.

How to disable your ad blocker for

Adblock / Adblock Plus

  • Click the Adblock/Adblock Plus icon, which is to the right of your address bar.
  • On Adblock click “Don’t run on pages on this domain”.
  • On Adblock Plus click “Enabled on this site” to disable ad blocking for the current website you are on. If you are in Firefox click “disable on “.

Firefox Tracking Protection

  • If you are Private Browsing in Firefox, “Tracking Protection” may cause the adblock notice to show. It can be temporarily disabled by clicking the “shield” icon in the address bar.


  • Click the Ghostery icon.
  • In versions before 6.0 click “whitelist site”.
  • In version 6.0 click “trust site” or add to your Trusted Site list.
  • In versions before 6.0 you will see the message “Site is whitelisted”.
  • Click “reload the page to see your changes”.


  • Click the uBlock icon.
  • Then click the big power button to whitelist the current web site, and its state will be remembered next time you visit the web site.
  • Then reload the page.

Url pharma #nectar #pharma

#url pharma



The world’s largest pharmaceuticals market is also the biggest market for Sun Pharma. We have been present in the US since 1996, working with the country’s healthcare system with a focus on generics, branded generics and over-the-counter (OTC) products. We are valued suppliers to the largest wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers. Being a vertically integrated company with a global presence, we have the flexibility to develop and manufacture products in the US as well as at other locations across the world. Our US headquarters are in Cranbury, New Jersey and we have distribution and customer service teams at multiple locations across the country.

Sun Pharma is present in the US through its own legal entities as well as its subsidiary, Taro Pharmaceuticals. Over the last few years, Sun Pharma has made several acquisitions in the US, including Caraco, DUSA Pharmaceuticals and Pharmalucence. Currently, we are market leaders in the generic dermatology sector, with a broad product portfolio for the treatment of Actinic Keratosis, Fungal Infections and Acne. We have strong capabilities in developing complex products and have a robust pipeline of 190 ANDAs, including high value First-to-File (FTF) opportunities.

Sun Pharma’s latest acquisition of a majority interest in Ranbaxy Laboratories Limited (Ranbaxy) and its Ohm Laboratories facilities in the New Jersey makes it the largest Indian pharma company in the US market, with a significantly expanded portfolio of life-saving and enhancing medicines. Sun Pharma and Ranbaxy have similar backgrounds and corporate values, with customer-oriented cultures and research-driven business models. Ranbaxy fits in well with Sun Pharma’s network of companies serving the US healthcare system.

We have built a strong reputation as a company that is market driven, focused on customer service and capable of offering a wide range of affordable pharmaceutical products. We continue to expand our product portfolio in the US market to the benefit of patients, prescribers and other stakeholders in the healthcare system.

Taro markets a broad range of prescription and OTC products. It is a leading manufacturer and supplier of topical dermatologicals. with a growing line of both, topical products and solid dosage formulations mainly used in cardiology and neurology therapies.

DUSA is focused on the development and marketing of dermatology products. DUSA’s flagship product, Levulan ® photodynamic therapy (PDT), is a technology platform used in conjunction with its proprietary light source, the BLU-U ® Blue Light Photodynamic Therapy Illuminator, for the treatment of minimally to moderately thick Actinic Keratosis of the face or scalp.

Pharmalucence is a manufacturer of non-cytotoxic human injectable pharmaceuticals, in either liquid or lyophilized form. It also specialises in radio pharmaceutical products. Pharmalucence’s 70,000 sq. ft. manufacturing facility is the region’s first unit to utilise fully automated and isolated aseptic technology in support of a wide array of needs, from small clinical fills up to full commercial scale production for markets worldwide.

Ohm Laboratories is a manufacturer of prescription and OTC drugs in solid dosage forms. Ohm is also approved to manufacture controlled substances by the US Drug Enforcement Agency (DEA). Its state-of-the-art laboratory, manufacturing and warehousing facilities are capable of handling high-volume products and large batch sizes, while its supply chain efficiency ensures seamless transportation to customer locations. Ohm is a frontrunner in bringing unique product deliveries and complex combinations to the market.

We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries of the world. Our presence in 65 key markets around the world is supported by 45 manufacturing facilities, across five continents. We have a multi-cultural workforce, comprising more than 30,000 employees of over 50 nationalities.

Patient Assistance Program: In partnership with Rx Outreach, Sun Pharma has launched a Patient Assistance Program. To learn more please click here

Dallas Texas Pharmaceutical Jobs #flynn #pharma

#pharmaceutical companies in dallas tx


Dallas, Texas Pharmaceutical Jobs

Looking for Pharmaceutical Jobs in Dallas, Texas. See currently available Pharmaceutical job openings in Dallas, Texas on Browse the current listings and fill out job applications. is the starting point for a job search in any pharmaceutical job in Dallas, Texas. We provide job resources for Pharmaceutical positions throughout the industry in Dallas, Texas. also provides Pharmaceutical jobs listings from around the United States. Job seekers can search and apply for jobs in Pharmaceutical by either city or state. is a pharmaceutical job search resource for job seekers in Dallas, Texas. Here you can easily find all Pharmaceutical jobs in Dallas, Texas, post a resume, and research your career.

Get started on your pharmaceutical job search in Dallas, Texas on today.

Current Dallas, Texas Pharmaceutical Jobs

Showing 1 to 20 of 268 jobs

Territory Sales Representative – Pharmaceutical Sales About Sebela Pharmaceuticals: Sebela Pharmaceuticals is a rapidly growing company located in.

As the only global provider of commercial solutions, Quintiles understands what it takes to deliver nationally and internationally. Our teams help.

DIRECT HIRE position with privately-held specialty pharmaceutical company focused on Pediatrics and Women’s Health. The Senior Management team at w.

Pharmaceutical Sales Representative – Neurology PDI at Publicishealth as a great opportunity for pharmaceutical sales representatives in the neurol.

Scientist needed, with strong expertise in a Pharmaceutical QC and/or R
/* 728×90, создано 05.02.11 */
google_ad_slot = “6127977750”;
google_ad_width = 670;
google_ad_height = 90;

Big Pharma Recruits Nurses to Fill Patient-Educator Roles #fosun #pharma

#big pharma jobs


Big Pharma Recruits Nurses to Fill Patient-Educator Roles

Patients with chronic diseases such as diabetes or multiple sclerosis often need help learning how to take and manage their many medications. At the same time, pharmaceutical makers need better ways to keep patients on those medications to both ensure the drugs efficacy and maintain sales.

For that reason, drug companies, including Berlex, Pfizer and Serono. are recruiting RNs to serve as patient educators, pioneering a new avenue for nurses who choose to practice in patients homes.

This novel role for nurses does indeed hold promise for all concerned. And many nurses will find career fulfillment in this job — if they re able to assure themselves they can ethically reconcile the dual roles of professional caregiver and Big Pharma employee.

It s a very important service that s much needed, says Kathryn Bowles, an associate professor at the University of Pennsylvania s School of Nursing. Patients with multiple chronic conditions see a variety of doctors and end up on 12 to 14 medications with complex rules and schedules. Errors and dangerous interactions happen.

Nurses working in doctors offices — and indeed, doctors themselves — often don t have time to explain how to take medications, show patients how to self-inject or follow up with patients regularly. By contrast, nurses working for drug makers can dedicate themselves to providing these and related services.

Nurses can find satisfaction in this occupation, Bowles says. It s such a critical part of managing chronic illness, she says. It requires independent decision-making, and there s variety. Every patient is unique.

According to Victoria O Donnell, an RN and dean of science and technology at Ca ada College, it s an excellent career path. All nurses, regardless of their degree, have been trained in health education, she points out.

It s one of the most fulfilling jobs a nurse can take, says Carolyn Silverman, a certified diabetes educator and field manager for Innovex, a division of Quintiles Transnational that provides patient education on contract to drug makers. These nurses help patients stay on life-saving medications in a variety of settings. Silverman has worked as a patient educator.

And once nurses establish themselves at pharmaceutical companies, a number of related career opportunities can open up in areas such as administration and clinical research .

Ethical Dimension of Nursing for Big Pharma

Is there a potential ethical clash between the RN s obligations as an employee of a pharmaceutical company and her fundamental professional responsibilities as a nurse? After all, the drug company is obliged to its stockholders to promote legitimate sales of its products, whereas a nurse is obliged to make sure the patient understands all his treatment options, whoever may profit from them.

That s something that needs to be explored, especially when there is a particular medication that s made by a variety of pharmaceutical companies, says O Donnell. It would almost be better if these nurses could do in-home care without being employed by the prescription drug maker.

Even as Big Pharma employees, nurses are patient advocates first, which raises other practice issues. If they are hired by a pharmaceutical company, will they be free to provide comprehensive service that looks at the whole package of medications the patient is on? Bowles asks. Will they look at ways to simplify the regime, perhaps even to recommend cutting a medication?

Nurses considering employment at Big Pharma would be wise to ask specific questions about how they will practice their profession and how the company addresses potential ethical conflicts.

Related Articles

6 Tips to Rewriting Your Resume for Pharmaceutical Sales #pharma #pharmaceutical #company

#pharma resumes


6 Tips to Rewriting Your Resume for Pharmaceutical Sales

Pharmaceutical sales is an immensely popular industry in the U.S. and abroad, both because of the excellent earning potential and the fact that sales reps often have the opportunity to create their own schedule rather than being tied down nine-to-five in an office. There is also a lot of growth in the field, from sales representative to district manager to regional or territory manager and finally to corporate roles.

With that in mind, it s no surprise that hundreds, even thousands, of resumes are received each month by pharmaceutical recruiters and the HR offices of pharmaceutical companies.

So how is someone supposed to stand out?

Well, the first thing is experience. If you have a strong background in sales, especially pharmaceutical sales or medical sales, you ve got an edge — maybe. Like everything else, there isn’t one hard rule on the ideal pharmaceutical sales candidate. For example, some companies prefer candidates without any industry experience — at least for those more entry-level positions — because they prefer new hires go through the company’s training program to learn their way.

But what about those job seekers who don t come from one of the top two backgrounds? In those cases, it s essential to highlight the pertinent, transferable skills you do have in such a way so that you attract the attention of hiring professionals. Let s look at how you can do this.

1. What’s on The Pharmaceuticals’ Wish List? This step involves identifying what skills and backgrounds companies look for in potential pharmaceutical sales reps and determining which ones you have, so that you can highlight them in your resume. Examples might be previous sales experience, account management, event management, communications, psychology, and customer service. If you are a recent college graduate, finding your transferable skills might be harder, so look beyond the classroom. Were you involved in fundraising activities? Work a retail job in the summer? Complete advanced projects for a particular class?

You might be wondering how some of these things are related to sales, but if you think carefully, you ll see that transferable skills are not always obvious but they are important. For instance, a background in psychology prepares a person for using subtle phrases and strategies to mold their opinion on something, such as a product, or to spot non-verbal clues to how a person is feeling about a product. Event management can be important because many pharmaceutical sales roles involve arranging meetings, lectures, and presentations with medical staff. Fund raising is a type of sales that is even harder to do than most – you re trying to get people to give you money and get nothing in return!

2. Turning Your Experience into Keywords. Now that you ve identified your skills, it s time to craft the proper phrasing in the resume. It s essential that you incorporate industry-specific keywords when you describe your experience and skills. What are some important keywords for pharmaceutical sales? Sales and Marketing, Account Management, Territory Management, Revenue Growth, Relationship Management, Customer Service, and Presentations, just to name a few. You can find plenty of the most common ones just by reading a handful of pharmaceutical sales rep job descriptions. But building keywords into your resume goes beyond the obvious. Sales is all about personality, so think about the attributes a good sales person has. They are aggressive without being obnoxious, they see ‘nos’ as opportunities, they are experts at the products they sell, and they are personable and friendly. While you don t want to focus too much on personality in a resume, you can usually sneak in some soft skills:

Aggressive but friendly Sales Professional with consistent history of penetrating and acquiring accounts.

Even if you don t have pharmaceutical or medical sales experience, that is a sentence that will appeal to just about any hiring manager when they see it at the top of your resume.

3. Branding Statements Taglines. A one or two-line branding statement will do wonders for your resume, and can help set you apart from other candidates. A good branding statement can be crafted by taking your 15-second elevator pitch (you do have one for your interview, don t you?) and reworking it so that it gives someone a great idea of who you are. Remember our sample keyword sentence from earlier?

Aggressive but friendly Sales Professional with consistent history of penetrating and acquiring accounts.

That s an excellent branding statement for a sales professional.

Following the branding statement, it s always a good idea to have a tag line. This is a related sentence or group of words that demonstrates the value you have to offer. Look at this example:

Award-winning Sales Representative – Top 5% Producer and consistent President s Club Winner

The branding statement and tag line also serve as excellent segues into your career summary.

4. Include the Right Information. This article isn t about the specifics of resume format. If you are looking to shape a resume for the pharmaceutical sector, you should already have a good idea of the different parts of a resume – summary, experience, education, training, etc. What we want to do now is remind you to include special information that you might have normally left off your resume. Do you have any previous experience in the healthcare field? Maybe you took some medical coding courses-add them to your training section. Perhaps in high school or college you volunteered at a hospital – put it in community service. In college, did you take some biology classes? Mention those in your education section. Anything you can add that is relevant to the pharmaceutical industry is going to help you. The same goes for individuals who might be coming from a healthcare background but don t have any sales experience. Did you take business courses in college or some sales training seminars earlier in your career? When appropriate, add them into the resume!

Another thing is to make sure you don t take anything for granted. Too often I see people put this in their education section:

Biology, College Name

To a reader, that means nothing. Did you take one biology course? Do you have an Associate s Degree? A Bachelor s? The resume isn t the place for hiding information or being vague. Here is how the education section should look:

Bachelor s of Science in Biology, School XYZ

Course work in Biology, School XYZ, including Anatomy, Advanced Biology, and Biochemistry.

Most pharmaceutical companies want their candidates to hold at least a Bachelor s; maybe others are not as strict. However, all of them value education and training, so be sure not to leave something off the resume that could help you.

5. Tell Your Story Correctly. Pharmaceutical companies and recruiters prefer to see not only what you have done, but how you achieved it. Some people make the mistake of only including half the information in their job descriptions; either they omit their achievements or they fail to show how they achieved their results. When you re writing your resume, be sure to use a Situation/Action/Result style to tell each story. This means describing the problem, showing the action you took, and listing the result.

In order to achieve sales growth for new product, developed multiple sales strategies that led to 18% market penetration six weeks ahead of projected timeline.

The situation was to grow the product, the action was to develop sales strategies, and the result was 18% market penetration. Pharmaceutical companies are very results-driven, so including as many quantifiable results as you can on the resume will be a big help in terms of getting you more interviews.

6. Review Your Resume. This is critical. After the resume is written, do not send it out to anyone until you and at least two other people (preferably someone with superior grammar and spelling skills) has looked it over. Remember, you are up against a lot of competition. Even a couple of typos, grammatical errors, spelling mistakes, or punctuation mistakes can mean the difference between getting an interview or having your resume end up in the trash.

Also important is providing complete contact information (omitting your email address or phone number is a major red flag in HR offices).

With these tips in mind, rebuilding your resume for pharmaceutical sales positions will not only be possible, but also effective.

Top 7 Pharmaceutical ETFs #mundi #pharma

#pharma etf


Pharmaceutical ETF List

Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.

Click on the tabs below to see more information on Pharmaceutical ETFs, including historical performance, dividends, holdings, expense ratios, technical indicators, analysts reports and more. Click on an ETF ticker or name to go to its detail page, for in-depth news, financial data and graphs. By default the list is ordered by descending total market capitalization. Note that ETFs are usually tagged by ETFdb analysts as more than one type; for example, an inverse gold ETF may be tagged as inverse and as gold and as commodity .

Note that the table below may include leveraged and inverse ETFs. Exclude Leveraged and Inverse ETFs

ETF Overview

This is a list of all Pharmaceutical ETFs traded in the USA which are currently tagged by ETF Database. Please note that the list may not contain newly issued ETFs. If you re looking for a more simplified way to browse and compare ETFs, you may want to visit our ETFdb Categories. which categorize every ETF in a single best fit category.

Assets in thousands of U.S. Dollars. Assets and Average Volume as of 2016-09-02 20:19:04 UTC

ETF Returns

This page includes historical return information for all Pharmaceutical ETFs listed on U.S. exchanges that are currently tracked by ETF Database.

ETF Expenses

The following table includes expense data and other descriptive information for all Pharmaceutical ETFs listed on U.S. exchanges that are currently tracked by ETF Database. In addition to expense ratio and issuer information, this table displays platforms that offer commission-free trading for certain ETFs.

Clicking on any of the links in the table below will provide additional descriptive and quantitative information on Pharmaceutical ETFs.

ETF Dividends

This page includes historical dividend information for all Pharmaceutical ETFs listed on U.S. exchanges that are currently tracked by ETF Database. Note that certain ETPs may not make dividend payments, and as such some of the information below may not be meaningful.

ETF Holdings

The table below includes basic holdings data for all U.S. listed Pharmaceutical ETFs that are currently tagged by ETF Database. The table below includes the number of holdings for each ETF and the percentage of assets that the top ten assets make up, if applicable. For more detailed holdings information for any ETF. click on the link in the right column.

ETF Tax Rates

The following table includes certain tax information for all Pharmaceutical ETFs listed on U.S. exchanges that are currently tracked by ETF Database, including applicable short-term and long-term capital gains rates and the tax form on which gains or losses in each ETF will be reported.

ETF Technicals

This page contains certain technical information for all Pharmaceutical ETFs that are listed on U.S. exchanges and tracked by ETF Database. Note that the table below only includes limited technical indicators; click on the View link in the far right column for each ETF to see an expanded display of the product s technicals.

ETF Analysis

This page provides links to various analysis for all Pharmaceutical ETFs that are listed on U.S. exchanges and tracked by ETF Database. The links in the table below will guide you to various analytical resources for the relevant ETF. including an X-ray of holdings, official fund fact sheet, or objective analyst report.

ETFs: ETFdb Realtime Ratings

This page provides ETFdb Ratings for all Pharmaceutical ETFs that are listed on U.S. exchanges and tracked by ETF Database. The ETFdb Ratings are transparent, quant-based evaluations of ETFs relative to other products in the same ETFdb Category. As such, it should be noted that this page may include ETFs from multiple ETFdb Categories.

Top 7 Pharmaceutical ETFs

Pharmajobs #global #pharm



Arzneimittelsicherheit / Drug Safety Jobs Stellenangebote

Riemser Pharma GmbH – Fachreferent Arzneimittelsicherheit (m/w) für den Bereich Medizin & Pharmakovigilanz gesucht in Greifswald.

Zeitpunkt einen Fachreferent Arzneimittelsicherheit (m/w) f r den Bereich Medizin & Pharmakovigilanz Referenz-Nr. G-16-07-PK-01, Ma nahmen, Interne und externe Kommunikation ber Arzneimittelrisiken, Aggregierte Berichte zur Nutzen-Risiko-Bewertung.

photonamic GmbH Co. KG – Mitarbeiter (m/w) im Bereich Qualit tssicherung und Pharmakovigilanz gesucht in Wedel bei Hamburg.

QualitätssicherungVerantwortung für Arzneimittelsicherheit in Zusammenarbeit mit einem externen Dienstleister, Abgeschlossenes Hochschulstudium mit einem medizinischen, pharmazeutischen, human­bio­lo­gischen oder anderem naturwissenschaftlichen

Winicker Norimed GmbH Medizinische Forschung – Pharmacovigilance Project Manager (m/w) gesucht in N rnberg.

mehrjährige Erfahrung im Bereich Arzneimittelsicherheit auf, haben ein fundiertes medizinisches Fachwissen und sehr gute Englischkenntnisse in Wort und Schrift. Sie zeigen ein sicheres Auftreten, ausgeprägte Teamfähigkeit und eine sehr sorgfältige

ber Optares GmbH Co. KG – Head of Medical Affairs (m/w) gesucht in Berlin.

Arzneimittelwirkungen (UAW) zur Abteilung Arzneimittelsicherheit Datenbank- und Internetrecherchen bzgl. Quellen/ Literatur, Quantitative und qualitative Erfolgskontrolle (z. B. Responsezeiten) Zusammenarbeit mit der PV zur Sicherstellung eines.

Pharmaceutical Marketing – Healthcare Marketing Services #pharmaceutical #contract #manufacturing #companies

#pharmaceutical marketing companies


Pharmaceutical Marketing

Pharmaceutical Marketing is a sector that Guerilla offers extensive international experience and expertise. Our pharmacy and healthcare marketing services span across pharmaceutical marketing, advertising, store design, digital. integrated campaigns, public relations and brand creation .

We understand that pharmaceutical and healthcare sectors are highly competitive sectors to operate within and for this reason we always ensure that our marketing communications provide our clients with the maximum return on investment and effectiveness. Below are just some examples of our pharmaceutical marketing activities:

If you are interested in finding out more, please download and view our Healthcare and Pharmacy work.

or contact James Allen who will be delighted to discuss what we can do for you.

Below are just some examples of our pharmaceutical marketing projects:


This is an example of how we named, created and then launched a Pan- European pharmacy retail and wholesale brand across eight countries.


After several years of successfully creating smoking cessation advertising campaigns Guerilla was chosen to launch a campaign targeting younger smokers to make them aware of the dangers of not kicking the habit.


Numark is an independent pharmacy chain with over 2500 members and Guerilla provides their business critical pharmaceutical digital services in the form of a public facing website and extranet.


BBI Healthcare approached Guerilla to assist them with a bilateral strategy and launch campaign for a new diabetes glucose monitoring product called Simplance. Our campaign targeted healthcare professionals to recommend the product to their patients and secondly directly to the consumer to create demand for the product through direct mail and press advertising .


Guerilla has extensive experience launching weight management products and when Optislim decided to launch Kim Kardashians Essentials Kit in the UK they chose Guerilla to plan and execute the integrated campaign .


Guerilla created the V name and brand for a brand new range of vitamins, minerals and supplements. V stands for vitality and the brand was rolled out across point of sale, digital, digital signage and packaging.


Following store re-designs for global retailers Holland & Barrett and GNC, Guerilla was asked to design a concept store for Rowlands Pharmacy that would be rolled out to an estate of pharmacists comprising over 500 stores.


Optimslim could see the value in driving the UK launch of their Kim Kardashians Essentials Kit through a public relations campaign that would involve Guerilla PR division arranging two launch events and achieving over £1.5 million of coverage.

Helvoet burns rubber to stay ahead of injectables market #akela #pharma #inc

#helvoet pharma


Helvoet burns rubber to stay ahead of injectables market

By Phil Taylor Phil Taylor 09-Jul-2007 2007-07-09T00:00:00Z

The world’s number two manufacturer of rubber components for pharmaceutical products, Helvoet Pharma, has broken ground on a new facility that promises to double or even triple its capacity to supply the fast-growing markets for injectable biologics and cancer drugs.

Belgium-based Helvoet is already a major player in the market for rubber components such as the stoppers for vials, and other elements such as plungers and tip caps used in syringes and insulin cartridges, ranking in the market somewhere behind West Pharma Services of the US and ahead of France-headquartered Stelmi. The company said the new facility, one of five it operates around the globe, would keep it among the top players in the sector in supplying the fast-growing market for components used in biologics, vaccines and oncologics.

The sensitive nature of these drugs means that considerable care has to be taken in selecting rubber components. Selecting a poor grade of stopper, for example, could allow leaching of elements into the vial that inactivate its contents, according to Helvoet’s marketing manager Paul Roosen. The new facility, which will take up 6,000 square metres, should add 500 million to 1 billion extra units to Helvoet’s current output of ‘several hundred million’ vial stoppers that are destined for these fragile products, said Roosen, who also noted that the firm’s total output of stoppers is in the region of 12 billion a year.

The main products made at the facility will be Helvoet’s FM457 range of stoppers, made of an inert elastomer that has been specifically designed to prevent leaching and so be suitable for filling sensitive drugs, as well as the firm’s Omniflex and Omniflex Plus ranges. The latter are said to be unique in the marketplace and are coated with an impermeable barrier to prevent leaching. Both products are important items for biologic and other fragile drugs – the Omniflex range is a little more expensive but can shorten time to market by making stability testing easier. Meanwhile, the FM457 range is suitable for sterilisation via gamma irradiation, an important factor in the production of ready-for-use (RFU) injectable products.

Other product lines destined for the new facility include Helvoet’s FM460 range of low-moisture stoppers and pre-filled syringe components (FM480). Roosen told that the new facility will allow it to carry out almost the entire production process – from pressing the mixed rubber into moulds through die cutting, washing/sterilising and packaging into RFU or ready-for-sterilisation (RFS) units – in a cleanroom environment. At the moment only the washing, sterilisation and packaging stages are carried out in cleanrooms.

Large companies want suppliers to uphold the same strict standards in their manufacturing processes as applied to the pharmaceutical sector itself, he said, adding that the plant – which represents an investment to the tune of €22m, should be operational by January 2009.

Helvoet also makes aluminium crimp seals for cartridges and aluminium seals and flip caps for vials and operates plants in Alkan, Belgium, Italy, the US and Germany.

Related News

Pharmaceutical companies in dallas tx #pharmaceutical #companies #in #orange #county

#pharmaceutical companies in dallas tx




Corporate Culture
Reata Pharmaceuticals is an entrepreneurial, clinical-stage, biopharmaceutical company built around a team of experienced drug industry professionals. We hire problem-solvers, trail-blazers, and people who want to make a difference. In addition to competitive salaries and an innovative work environment, we offer our employees a comprehensive benefit package, including medical, dental, and 401k. All employees are also granted stock options.

Open positions and job descriptions will be posted in the sections below.

About Dallas
Reata is located in Irving, Texas, in the center of the Dallas-Fort Worth Metroplex. The Dallas-Fort Worth area is home to five major sports teams, top Zagat-rated hotels and restaurants, many Fortune 500 companies, major art and science museums including the Perot Museum of Nature and Science, the Dallas Museum of Art, the Nasher Sculpture Center, and the Kimbell Art Museum, and many performing arts venues including Bass Hall, the Meyerson Symphony Center, and the AT T Center for the Performing Arts.

Reata will only accept applications from individual candidates.

Drug Injury Attorney in Dallas, Texas #fierce #pharma

#pharmaceutical companies in dallas tx


24/7 AVAILABILITY (214) 219-4878

Dallas Drug Injury Lawyer

Drug Injuries and Pharmaceutical Liability

Medicine has come a long way from the early 20th century and the experiments of Alexander Fleming and Paul Ehrlich. The development of antibiotics such as penicillin ushered in a new wave of medicine which provided vaccines to children to combat most of the deadly childhood illnesses such as measles and polio. Since this point, medicine and antibiotics have grown to large proportions and are now used on a daily basis. We place our trust in pharmaceutical companies and when a drug causes severe injuries, the responsible party deserves to be held accountable and a strong Dallas drug injury lawyer can help you get the compensation you deserve.

Pharmaceutical Companies

The pharmaceutical industry has shifted from an industry which helps people to one which desires a profit. Profit only comes with new medicinal revenue. As a result, pharmaceutical companies often attempt to increase profits by hurriedly rushing a new drug to market without taking the proper precautions. They additionally attempt to incentivize doctors and health care professionals who will boast the drug to their patients before any medical tests have proven any harmful effects of the drug.

However, this lack of testing can lead to irreparable damage which pharmaceutical companies and participating health care professionals should be responsible for.

Drug Injuries

Drug injuries have become so widespread recently and touted throughout commercials and billboards that it makes it difficult to trust any pharmaceutical company. Several of the main drugs known to cause injuries include:

  • Xarelto: Prescription blood thinner manufactured by Bayer and marketed by Johnson Johnson.
  • Yaz: birth control medication which has been linked to blood clots and increased potassium levels in the blood.
  • Chantix. smoking cessation drug which is linked to birth defects.
  • Actos and Byetta: Diabetes drugs which have been linked to severe organ damage.
  • Eliquis. Prescription blood thinner manufactured by Bristol-Myers Squibb and Pfizer.
  • Topamax: migraine drug which has been linked to birth defects.

There are many other types of drugs that lead to serious injuries, many even fatal. If you have been injured from a drug produced by pharmaceutical companies, do not hesitate to contact our Dallas personal injury attorney Jeff Benton today.

The Benton Law Firm | Dallas Pharmaceutical Liability Attorney

The Benton Law Firm handles many drug injury cases throughout the Dallas area, including the drugs listed above and many more. We understand the amount of trust you place in pharmaceutical companies and the feeling once a drug is found to injure you instead of help you. Modern medicine has evolved to prevent serious injuries from occurring and when these drugs instead cause the injuries, it leads many of us fearful to take any helpful antibiotics. If you or a loved one have been injured by a drug, you should not be forced to pay for any medical expenses associated with your injuries. Contact our law offices today to set up your initial consultation with our attorney, and our attorney will begin putting together a strategy to pursue a case against the drug manufacturer. Antibiotics and other medicine sometimes cause more harm than good, but if you and other injured clients continue to bring claims against the pharmaceutical companies, you will effectively prevent other patients from ingesting dangerous drugs.

Practice Areas

Request a free consultation

Delve Deeper – Marketing & Brand Management #eisai #pharma

#pharma marketing jobs


Delve Deeper – Marketing Brand Management

A job in pharmaceuticals marketing and brand management can be an exciting and rewarding career, with fantastic prospects for qualified and motivated candidates.

With the continually changing nature of the pharmaceuticals marketing and brand management sector, those seeking a career in this industry should understand that keeping track of the latest innovations will help ensure success.

Work in the pharma marketing and brand management sector can also be very competitive and job seekers should persevere and enlist the guidance of a recruitment professional that understands the market and industry.

As a specialist in pharmaceuticals recruitment, Hays Life Sciences provides staffing solutions for CROs, big pharma and life sciences companies around the world.

We are dedicated to filling each vacancy with the best available candidate and we undertake a range of unique recruitment methods to ensure this happens. Options include multiple hiring and global searches, in which we can advice on issues such as cultural inductions and work permits.

A career in pharma marketing and brand management

One of the best ways to get started in marketing and brand management within the pharmaceuticals industry is to find a trainee position. Candidates should generally hold a life sciences degree, with a minimum classification of 2:1, and knowledge of marketing, brand management and company image are important.

For those with previous experience in marketing and brand management jobs in other sectors, it is possible – but sometimes difficult – to transfer into the pharmaceuticals industry. Those considering this sort of sideways movement in their career – even if it’s from a similar industry, such as clinical research or biotechnology – may find it necessary to take a small step downwards in order to reach their full potential in the long term.

Both contract and permanent opportunities for pharmaceutical marketing and brand management positions exist, but the contract and interim roles are usually reserved for individuals with significant relevant experience.

There is great scope for pharma marketing and brand management positions within Europe and North America and it is common for those in the sector to transfer between EU countries to build their careers.

The remuneration for a position in pharmaceuticals marketing and brand management will depend on the responsibilities of the role and the candidate’s previous experience, as well as the hiring company and its location. While annual salaries vary, they are generally in the area of 40,000- 70,000.

Roles in pharma marketing and brand management

Jobs in pharmaceuticals marketing and brand management can be quite varied. But whatever role a candidate decides to pursue, it will require excellent verbal and written communication skills.

Additionally, experience with activities such as new product launches and bid defence can be very beneficial to candidates seeking a position in marketing and brand management.

Local and international product managers are important members of the marketing and brand management team. They manage the marketing strategies and work to understand customer needs, developing plans and providing training for sales forces and clinicians.

Positions for marketing and brand management managers are prevalent throughout the pharma, biotech and medical device industry. They set up strategies for products, liaising with consulting firms and communicating information to the sales team.

Marketing and brand management directors oversee the marketing and sales plans, ensuring that they are successfully managed and monitored.

Find a marketing and brand management job with Hays Life Sciences

At Hays Life Sciences, we work closely with both job seekers and employers to make sure that every vacancy for pharmaceuticals marketing and brand management is filled with the most suitable applicant available.

As one of the world’s leading recruitment and staffing companies, we work with CROs and big pharma companies in 25 countries to fill permanent, temporary and consultant marketing and brand management jobs at the mid- to upper-levels.

We have an expert team of staffing specialists who have undergone meticulous training to ensure that they have a strong understanding of the fields in which they are working.

We take great pride in our attention to detail; we work hard help employers who are looking marketing and brand management candidates, as well as job seekers, find a solution that suits their requirements.

Future of Pharmaceutical Industry – pharma innovation gaps, patent expiry, empty drug pipelines #biotech #companies

#future of pharmaceutical industry


The pharmaceutical industry is facing huge challenges – described in video above and in powerpoint slides below. Notes on content: Over the last five years there has been serious lack of innovation in pharma companies and product pipelines have been emptying. It takes up to 15 years and $1 billion in investment to bring a single new treatment to market, after which there may be as little as a decade left before patents expire. But before that happens there may be serious threats to the pharmaceutical industry from generic manufacturers. And at any point in development or after launch, an adverse problem can result in product recall. For these reasons Pharmaceutical companies tended to focus on the search for blockbuster drugs in the early years of the 2000s: drugs with expected revenues of more than $1bn a year.

Need a world-class pharma keynote speaker? Phone Patrick Dixon now or email.

The top 10 pharmaceutical companies have enjoyed research and development budgets greatert than the combined GDP of the world’s poorest 130 nations, yet have produced only 30% of new drugs being approved each year. The rest have largely been developed by some of the 4,000 small biotechnology companies, working on large molecule therapeutics.

It is an immensely complicated and risky process, working through laboratory studies, animal studies and then clinical trials. A key issue for the future will be routine gene profile typing and pharmacogenomics – or matching drug therapy to someone’s genetic code. This will result in better targetting of the most effective therapies in each situation, but also in lower sales for each therapy since only those people in whom it is most likely to work will actually receive it.

Watch out for a shift from health care or treating sickness, to wellness, disease prevention, enhanced performance and lifestyle drugs. This is the age of Viagra-like drugs, designed to rejuvenate, or to increase deteriorating function such as memory. But drugs developed for a condition like Alzheimers will also be widely used or abused, if they are shown to really stimulate human memory capacity for example.

Expect a new emphasis also on common cellular mechanisms of disease. There are only a few ways in which human cells age for example. If we can block one or two of these mechanisms the result may be an effective treatment for a wide range of conditions which are more common as people get old – and remember that diseases of ageing drive most health care spending in developing nations. Indeed 75% of health spending in America and Western Europe is on those over the age of 65.

Watch out for major shifts in government purchasing policies, changes in US medicare and in health insurance cover. Over the counter and pharmacists sales will grow rapidly, helped by deregulation in developed nations, allowing more products to be available without prescription, “over the counter”. Expect huge growth in so-called nutraceuticals (foods with active health-stimiulating ingredients) and cosmetics with all kinds of anti-ageing properties.

While most budget will be spent solving common chronic diseases, expect innovation in childhood diseases, with a special focus on emerging nations, funded by philanthropic foundations. Expect major progress with new vaccines. Rheumatoid arthritis and asthma share a root cause in abnormal immune systems – expect huge research into tackling auto-immune problems.

Expect also big investment into next generation antibiotics to solve multiple drug resistance problems, which are one of the major challenges for the future.

Other issues include future health funding and ageing populations – contrast with emerging markets. Health economics: treatment access and justice.

Winning the Public Debate about Pharma

Problem: Negative public image of big pharma / pharmaceutical industry major players

Impact: Hostile regulators, hostile media, hostile web communities, aggressive activists and analysts, loss of best talent to other industries / biotech, difficult pricing negotiations with governments etc. Cost to whole industry could be billions of dollars a year.

Cause: Confused messages directed at analysts and consumers. Same kind of problem seen in insurance and energy industries. A simplification: Analysts: bottom line, return on equity, competitive advantage, keeping product prices high, exploiting market gaps – and by implication making as much money as possible out of as many sick people as possible. Consumers: saving lives, helping humankind, helping get safe, low cost treatments to all who need them – and by implication less concerned about things like intellectual property rights or threat from generic manufacturers. Consumers often find messages aimed at analysts offensive and bordering on unethical. Analysts often find messages aimed at consumers worrying and maybe unbusinesslike.

Solution: simple, powerful message revealing the truth about Wyeth: an inspiring, world-changing and business success story. Use BP Chairman’s and HSBC Chairman’s approach – similar messages in 2005 to defend record profits in both organisations to hostile media. Each Chairman adopted a simple, powerful and compelling message designed to appeal to every audience and market. Pharma industry has not managed this effectively (yet) – a surprise since nature of pharma should make task relatively easy.

Result: better media coverage, better corporate image, better government relations, better talent recruitment and retention, better morale and productivity.
Content of message: How pharmeceutical industry is helping create a better kind of world for individuals, families, communities, wider humanity. Urgent need for new treatments (mainly to treat older people), and how pensioners and pension funds are providing 75% of the investment needed to develop them. How pharmaceutical industry not only is touching millions of lives, but is also providing financial security for millions of pensioners, by investing wisely in innovative, affordable treatments that really make a difference. Product pipeline, outlook etc.

Need a world-class pharmaceutical industry keynote speaker? Phone Patrick Dixon now or email.

Slides / keynote presentations on

Future of the pharmaceutical industry – for Wyeth (2008)

Future of the pharmaceutical industry – for International Conference for Pharmaceutical Medicine (ICPM 2008)

Pharma india

#pharma india


AstraZeneca Pharma India Limited (AZPIL) has interests in seven crucial areas of healthcare:

• Brilinta® (Ticagrelor Tablets 90mg)

• Betaloc® (Metoprolol Tartrate Tablets IP 25mg, 50mg 100mg)

• Seloken XL® (Metoprolol Succinate Extended Release Tablets USP 25mg, 50mg 100mg)

• Imdur® (Prolonged Release Isosorbide-5-Mononitrate Tablets BP 30mg 60mg)

• Crestor® (Rosuvastatin Tablets IP 5mg, 10mg, 20mg 40mg)

• Seloram™ (Metoprolol Succinate Extended Release Ramipril Tablets 25/2.5mg, 25/5mg 50/5mg)

• Vigocil® (Voglibose Orally Disintegrating Tablets 0.2mg 0.3mg)

• Vigocil M® (Voglibose and Metformin Hydrochloride Tablets 0.2/500mg 0.3/500mg)

• Nitract SR™ (Nitroglycerin Sustained Release Capsules 2.5mg 6.5mg)

• Valfect™ (Valsartan Tablets 40mg, 80mg 160mg)

• Olways™ (Olmesartan Medoxomil Tablets 20mg 40mg)

• Olways H™ (Olmesartan Medoxomil and Hydrochlorothiazide Tablets 20/12.5mg 40/12.5mg)

• Olways AM™ (Olmesartan Medoxomil and Amlodipine Besilate Tablets 20/5mg)

• Onglyza® (Saxagliptin Tablets 2.5mg)

• Kombiglyze XR™ (Saxagliptin Metformin HCl Extended Release Tablets 2.5/1000mg 5/500mg)

• Byetta™ (Exenatide Injection 250 mcg/mL, 1.2mL 2.4mL prefilled pen]

• Mit’s Linctus Codeinae Co® (Codeine Phosphate and Chlorpheniramine Maleate Syrup)

• Mit’s Linctus DX™ (Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride and Chlorpheniramine Maleate Syrup)

• Bricarex® (Terbutaline Sulphate and Guaiphenesin Syrup)

• Bricarex A® (Ambroxol, Terbutaline Sulphate and Guaiphenesin Expectorant)

• Bricacef™ (Cefpodoxime Proxetil and Potassium Clavulanate Tablets 200/125mg)

• Bricacef DT™ (Cefpodoxime Proxetil and Clavulanate Potassium Dispersible Tablets 100/62.5mg)

• Bricacef PED® (Cefpodoxime Proxetil and Clavulanate Potassium for Oral Suspension 50/31.25mg)

• Bricanyl Syrup® (Terbutaline Sulphate Syrup)

• Symbicort® (Budesonide/Formoterol Inhalation Powder 160/4.5mcg/dose)

• Prostodin® (Carboprost Tromethamine Injection IP 125mcg 250mcg)

• Cerviprime® (Dinoprostone Gel)

• Partocin™ (Oxytocin Injection 5IU)

• Arimidex® (Anastrozole Tablets IP 1mg)

• Nolvadex™ (Tamoxifen Tablets IP 10mg)

• Iressa® (Gefitinib Tablets IP 250mg)

• Zoladex® (Goserelin Acetate Injection 3.6mg Goserelin Acetate Depot Injection 10.8mg)

• Casodex® (Bicalutamide Tablets USP 50mg)

• Faslodex™ (Fulvestrant Injection 250mg)

• Meronem® (Meropenem Injection IP 500mg 1g)

• Vancocin CP® (Vancomycin Hydrochloride for Intravenous Infusion IP 500mg)

• Enclere® (Cefoperazone and Sulbactam for Injection 500/500mg 1000/1000mg)

• Enclere Forte® (Cefoperazone and Sulbactam for Injection 1000/500mg 2000/1000mg)

• Remergin™ (Colistimethate Sodium for Injection BP 1MIU)]

• Xylocaine® (Lignocaine Hydrochloride Injection IP 2%)

• Xylocaine Viscous® (Lidocaine Hydrochloride Oral Topical Solution USP)

• Sensorcaine® (Bupivacaine Injection IP 0.25% 0.5%)

• Sensorcaine Heavy® (Bupivacaine Hydrochloride in Dextrose Injection USP)

• Diprivan® (Propofol 1%W/V Injection)

• Naropin® (Ropivacaine Hydrochloride Injection USP 0.2% 0.75%)

• Neksium Tablets™ (Esomeprazole Tablets 20mg 40mg)

• Neksium Injection® (Esomeprazole Sodium Powder for Solution for Injection 40mg)

*In alliance with Bristol Myers Squibb

Adverse event reporting

All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug’s therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable. AstraZeneca is committed to protecting the safety of patients who receive our products.

Report any suspected Adverse Events to AstraZeneca medications through the established procedures.

Why report Adverse Event?

  • Adverse Event reporting helps AstraZeneca to identify rare and very rare adverse effects
  • Reporting leads to regular review of safety database for new risks or signals.
  • Adverse Event reports help to provide current and accurate updates on safety profiles of the drugs
  • Adverse Event reports help to identify different profiles of known adverse reactions with regards to severity, nature or outcome

What is an adverse event?

An Adverse Event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.

You may be more familiar with the tern “side effect”

What does this include?

Adverse Event includes undesirable medical condition that can be symptoms (for example nausea, chest pain), signs (for example tachycardia, enlarged liver) or the abnormal results of an investigation (for example laboratory findings, electrocardiogram). Adverse Events are not necessarily caused by the medication – the event just needs to have occurred after taking a medicine and AstraZeneca also collects the reports of :

  • Drug exposure during pregnancy and breastfeeding
  • Lack of drug effect
  • Drug overdose or medication error
  • Drug abuse or misuse
  • Transmission of infectious agents via an AstraZeneca product
  • Drug Interactions

1. Patient identifier

• Who experienced the Adverse Event?

• Patient and reporter identifier is important to avoid case duplication and facilitate follow up of appropriate cases

• The term identifiable in this context refers to the verification of the existence of a patient (e.g. you might provide: sex, age etc)

2. Event description

• What was the Adverse Event?

• Describe the nature of the adverse event, any signs and symptoms and outcome of the event

• Who is reporting the Event?

• Give your name, address and phone number as you may need to be contacted for further information

• If you are reporting on behalf of a healthcare professional (e.g. if you are a sales representative), be prepared to also give their details.

• What AstraZeneca product was taken by the patient?

• Provide the name of the AstraZeneca product taken by the patient

If you do not have all the details listed above. please still report the Adverse Event. In addition, you can report any other details you have about the Adverse Event.

Report the Adverse Event even if you don’t think it is serious, relevant or caused by AstraZeneca product.

You can report the Adverse Event by using the Adverse Event Report Form. (Insert docs)

Contact AstraZeneca Patient Safety at

Tel: +91-80-67748000 (Ext. 8458)


Please click here to read more about the CSR Policy (PDF 87kb)

2. Young Health Programme

Young Health Programme is AstraZeneca’s global community investment programme and is designed to help young people in need around the world deal with the health issues they face and improve their chances for a better life in the future.

In India, YHP was started in November 2010. The programme is initiated in five resettlement colonies around New Delhi. The focus area of the programme includes addressing health issues related to Sexual and Reproductive Health, TB, Dengue, Malaria, Substance Abuse and Life Style diseases.

YHP India has directly been able to reach out to 89,493 young people (40,271 boys and 49,222 girls), and has influenced 84,387 wider community members, including health professionals, educators and policy makers. The YHP trained an additional 818 adolescents as Peer Educators during the second year of operations. The establishment of 15 Health Information Centres (HICs) which act as a forum for the youth. The second vital approach is the training and support of 1,581 Peer Educators (of which 814 are girls, who are actively responsible for delivering health messages to other youngsters in school and communities. YHP India continues to enhance knowledge on health issues and ways to cope with it for adolescents and hopes to reach a larger audience as the year’s progress.

Please click here to read more about the Young Health Programme

Investor Relations

You are now leaving

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

Multiple Vacancies in Marketing, Sales Officer, Area Sales Manager, Regional Sales Manager, F & D,

#pharma marketing jobs


Multiple Vacancies in Marketing, Sales Officer, Area Sales Manager, Regional Sales Manager, F D, Production, QC in ORDAIN HEALTHCARE

ORDAIN was created with a simple objective of providing Quality Drugs… Quality Life to all the precious human life. Our mission is to continuously innovate methods of “Preserving and improving quality of human life” by providing superior products and services with uncompromised Quality Everywhere… Every time…
We are ranked 79th position in all Indian Pharmaceutical Market and 44th position in Tamilnadu in our represented markets in India by ORG-IMS. We are proud to have achieved 120th rank in C-MARC prescription rating in all Indian Pharmaceutical Market and We are rated in BBB- by CRISIL.

Post: Marketing, Sales Officer, Area Sales Manager, Regional Sales Manager, F D, Production, QC

B-Pharm graduates with MBA or Postgraduate Diploma in Marketing who is having Field Experience for 2-3 years can apply.Age criteria not more than 30 years.

Sales Officer
Fresh Graduates of Pharmacy, Science, BBA, D.Pharm, or any other discipline can apply. Age criteria not more than 22 years.

Area Sales Manager
Successful medical representatives working for leading pharma companies having experience around 3-5 years can apply. Age criteria not more than 30 years.

Regional Sales Manager
Successful first line Managers working in leading pharma company having managerial experience around 2-4 years can apply. Age criteria not more than 35 years.

Formulation Development
Ph.D. in Pharmaceutical Science with relevant experience.

Production QC
B.Pharm or M.Pharm with 2 to 3 years relevant experience

Additional Information:
Experience: 1-4 years
Location: Chennai
Education: B.Pharm, B.Sc, M.Pharm, M.Sc, Ph.D, MBA
Industry Type: Pharma/ Biotech/Clinical Research
Functional Area: Production, QC, Sales

Medical Device Marketing, Biotech – Pharmaceutical Marketing Company #pharma #packaging #solutions

#pharmaceutical marketing companies


Irvine, CA and Minneapolis, MN (August 10, 2016) – DevicePharm, a marketing strategy and integrated marketing communications firm serving medical device, biotech, diagnostics, and pharmaceutical companies, announced today that Christine Horton has joined the firm as Vice President. She will be based in the firm’s rapidly growing Minneapolis office and will serve as a member of the leadership team.

ReShape Medical ® Website Wins Summit International Emerging Media Award

The ReShape Medical website,, has received widespread recognition from industry groups and physicians. Summit International Media recently added to the notoriety by recognizing the ReShape Medical website with its Leadership Award in the category of Health and Wellness Websites.

DevicePharm has been recognized as a Foundational Member of Medical Alley, the Minnesota-based organization focused on growing one of the world’s most prolific centers of healthcare technology and delivery innovation.

UK Trade Investment — the business development arm of the British Consulate — invited DevicePharm CEO Chief Strategy Officer, Clay Wilemon, to present to UK medical firms during a February conference.

We have helped our clients successfully define and launch over 500 medical brands.

Pharma 2020: Marketing the future – Which path will you take? #pharmaceutical #manufacturing #industry

#pharmaceutical marketing companies


Pharma 2020: Marketing the future

Which path will you take?

By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a target-market approach to increase revenue.

Pharma 2020: Marketing the future – Which path will you take? the third in the Pharma 2020 series, outlines a confluence of dynamics that lead to a new marketing and sales system with a smaller, more agile and smarter sales force. The pharma industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies will need to demonstrate that their brand adds value to patients and they will have to offer a package of products and health services that the market not only wants and needs but is willing to pay a premium for. The paper highlights some very strong facts related to the need for Pharma to change its marketing and sales functions in order to sustain future growth and performance.

This report outlines in some detail what those changes in the business environment will be and provides pharma companies with indicators of organisational and operational structure that could influence their success and readiness to compete.

This report highlights the fundamental dynamics the industry faces that are reshaping the pharmaceutical marketplace:

  • Chronic disease is soaring
  • Healthcare policy makers and payers are increasingly mandating what doctors can prescribe
  • Pay-for-performance is on the rise
  • The boundaries between different forms of healthcare are blurring
  • The markets of the developing world, where demand for medicines is likely to grow most rapidly over the next 13 years, are highly varied
  • Governments are beginning to focus on prevention rather than treatment
  • Regulators are becoming more risk-averse

In order to be successful, companies will need to stop the aggressive marketing focusing only on the product of the current model and:

  • Recognise the interdependence of the payer, provider and pharmaceutical value chains
  • Invest in developing medicines the market wants to buy
  • Adopt a more flexible approach to pricing
  • Develop plans for marketing and selling specialist therapies
  • Manage multi-country launches and live licensing
  • Form a web of alliances to offer supporting services
  • Create cultures that are suitable for marketing specialist healthcare packages
  • Develop marketing and sales functions that are fit for the future and a knowledge based commercial organisation

Pharma 2020: The vision. first in the series highlights a number of issues that will have a major bearing on the industry over the next 11 years. Thepublication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provideto shareholders and society alike.

Pharma 2020: Virtual R D. the second in the series explores opportunities to improve the R D process. This paper proposes that new technologies willenable the adoption of virtual R D and by operating in a more connected world, industry, in collaboration with researches, governments, healthcare payersand providers, can address the changing needs of society more effectively.

Pharma 2020: Challenging business models. the fourth in the Pharma 2020 series, this report explains why Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020 and why more creative collaboration models may be more attractive. The paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry.

Pharma 2020: Taxing times ahead. the fifth in the series focuses on the industry’s opportunities and challenges from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing pressure on effective tax rates within the industry. It also shows how companies can adapt their tax planning to support the provision of outcomes-based healthcare and remain competitive.

Pharma 2020: Supplying the future — Which path will you take?
How pharma companies will have to develop different supply chain models for different product types and patient segments, learn to use their supply chains as a means of market differentiation and source of economic value, and recognise the key role information will play flowing upstream to drive the downstream flow of products and services.

Business alliance in pharmaceutical additives between Asahi Kasei and SPI Pharma #luye #pharma

#spi pharma


Business alliance in pharmaceutical additives between Asahi Kasei and SPI Pharma

December 15, 2015
Asahi Kasei Chemicals Corp.

Asahi Kasei Chemicals and SPI Pharma, Inc. have agreed to form an alliance in the field of pharmaceutical additives. Beginning in January 2016, each company will sell the other’s pharmaceutical additives in the respective markets of Japan and North America.

The pharmaceutical additives business of Asahi Kasei Chemicals is led by Ceolus microcrystalline cellulose (MCC) which features a superior balance of compactibility and flow in the tableting process. The product lineup includes specialty grades that enable soft (low-pressure) tableting and provide sufficient hardness with low addition rate, which are suitable for various challenging tablet formulations including orally disintegrating tablets (ODTs). Asahi Kasei Chemicals is expanding in global markets with specialty grades to further strengthen operations.

SPI Pharma is headquartered in the US and is a fully owned subsidiary of Associated British Foods of the UK, with a product portfolio of functional excipients, antacid actives, vaccine adjuvants including Mannogem Mannitol for swallow tablets as well as chewable tablets and lozenges and Pharmaburst , a fully formulated drug delivery system for ODTs.

The business alliance announced today will leverage the complementary products and sales channels of the two companies for mutual benefit.

Reciprocal sale in Japan and North America

Asahi Kasei Chemicals will become the exclusive distributor in Japan for Mannogem and Pharmaburst while SPI Pharma will become the exclusive distributor in the US and Canada for specialty grades of Ceolus and Celphere MCC spherical seed cores for pharmaceutical applications.


In addition to developing markets by leveraging the complementary sales networks of Asahi Kasei Chemicals, with a leading position in Japan and Asia, and SPI Pharma, with strength in North America and Europe, the two companies will study the development of new products utilizing their respective technological strengths. Through this alliance, both Asahi Kasei Chemicals and SPI Pharma will seek to make a greater contribution to drug development and reinforce their presence in the global healthcare market.

Profile of SPI Pharma, Inc.

  1. Headquarters Wilmington, DE, USA
  2. President Rana Kayal
  3. Operation Manufacture and sale of pharmaceuticals and additives for pharmaceuticals and health foods
  4. Shareholder Associated British Foods plc (100%)
  5. Operating bases US, France, India

Hi-Tech Pharmaceuticals #pharmaceutical #products

#hitech pharma


In Pakistan, growth of poultry sector during last three decades has been quite gradual. After that when hit by Bird Flu syndrome and other market factors at national and international level it caused a prolonged spell of recession. By 2008 size of poultry in Pakistan had shrunk by 35 40%. Continually increasing cost of production, grain storage, energy crises, disease pressure and glooming market conditions not only shattered farmers confidence, keeping them away from further investment but also resulted in half hearted usages of vaccines and other medicines by them. Realizing the need to revive farmer s confidence in sustainable development of poultry, Hi-Tech Group as a major stakeholder moved forward and entered into field of quality poultry vaccines (live and killed) and medicines for livestock and companion animals.

Established in October 2007, Hi-Tech Pharmaceuticals had an agreement with ‘M/S Fort Dodge Animal Health’ (now part of ‘pfizer’). a renowned manufacturer of vaccines and other medicines for poultry and animals. This agreement defined us as their Independent Executive Sale Agent / Distributor of full range of products in Pakistan. These products include poultry biological ( live killed ). canine vaccine and products, livestock biological, injectable and de-wormers from FDAH manufacturing sources at USA, Netherlands and Brazil.

Hi-Tech Pharmaceuticals is determined to ensure strict observance and adherence to quality conditions for import, storage, distribution and delivery of authorized biological as outlined by Ministry of Health, Government of Pakistan and United States Drugs Agency. It has established and experienced distribution and sales network across the country. Its processional sales teams understand the requirements with there tools and experience of handling biological. Sub distributors at area basis covering major poultry zones in the country also have assured arrangement for storage and distribution of biological sustaining +2 + 8 C temperature.

A state of the art Cold Room for storage and cool chain for distribution of temperature sensitive drugs (biological/vaccines) being essential and important prerequisite, have been installed at the purpose built site at Lahore. All deliveries from Air Port to Company s Cold Room and Cold Room to Sub-distributors / dealers / farmers are made under strict quarantine control.

Financial worth, self usages of FDAH products / biological, unique and vast network with great influence in Pakistan Poultry Market places Hi-Tech Pharmaceuticals unmatched. Within short span after it commenced operation, Hi-Tech Pharmaceuticals has been acknowledged as a quality conscious company in synergy with international standards.It stands by the commitment to provide regular availability of the vast range of effective products to consumers who depend upon us.

Eisai Inc #la #pharma

#eisai pharma


Welcome to Eisai Inc

Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd. a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business.

Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co. Ltd. which has a strong and lasting commitment to the U.S. market.

Our heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company – a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Our ability to forge strong alliances gives us a competitive edge.

In the United States, our rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage our operations. Eisai employees personify our values of integrity, respect, professionalism, quality and teamwork.

As you continue exploring our corporate web site, you will learn more about how our commitment to hhc is a motivating force for everything we do and everything we produce.

This is the website of Eisai Inc. a US company. This site is intended for US residents only. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

Copyright © Eisai Inc. 2016. All Rights Reserved.

Please note that by clicking on this link, you will be leaving the Eisai Inc. US website and be taken to the Eisai Co. Ltd. Japan website

Please note that by clicking on this link, you will be leaving the Eisai Inc US website and be taken to an external website.

You are now leaving the Eisai Inc. US website and going to Morphotek, a wholly-owned subsidiary of Eisai Inc.

Preparing your Resume #alliance #pharma

#pharma resumes


Preparing your Resume for a Pharmaceutical Job

First impressions are lasting ones

You ve got precious little time to catch a recruiter’s eye, which is why you need to make sure your resume is as effective as possible. Here are a few pointers to help get you on an AstraZeneca recruiter’s short list:

  • Emphasise what you’ve done, not what you want to do
  • Find experiences in your life where you’ve demonstrated the behaviors listed in a job description
  • Highlight your contact information and make sure your voicemail message is clear
  • Make pertinent information like education, professional experience, leadership roles, team participation and volunteer experience easy to find
  • Be honest about your experiences
  • Format your resume so it’s readable, concise and in a recognisable font
  • Don’t be too lengthy. One page is preferable, but two can be acceptable if you’ve got a lot of experience
  • Use descriptive verbs to present your experiences
  • Be specific and have evidence to support your statements
  • Title your sections clearly: Education, Work Experience, Skill Sets, Activities/Achievements
  • Keep it short, sweet and to the point

What to avoid on a Pharmaceutical Resume

  • Wordiness. Use short sentences. Treat your resume like an advertisement and use complete phrases
  • Excessive use of borders, italics and fancy fonts. They don’t upload cleanly into online systems
  • Small fonts. Stick to 10-12 point
  • Too much bold type. Only enbold major achievements

Last reviewed: January 16, 2015

Further Reading

Important Notice

Have you ever been approached by anyone appearing to be offering a job for which you have not applied for or seen a job advert which does not look genuine?

It has come to our attention that emails and job adverts have been created and circulated by unknown individuals for the purpose of attempting to defraud candidates.

Potential candidates should be wary of approaches that appear to be offering a job for which they have not applied, especially if personal details or money must be sent in order to proceed with the recruitment. Neither AstraZeneca nor any commissioned third parties recruit in this manner. Such approaches are almost certainly fraudulent attempts to gain details of identity for illegal use.

AstraZeneca is taking all necessary steps to investigate this matter further.

AstraZeneca 2016. All rights reserved.

AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law.

Helvoet Pharma invests Rs 120 crore in Pune plant #contract #pharma

#helvoet pharma


Helvoet Pharma invests Rs 120 crore in Pune plant

BS Reporter | Mumbai/ Pune Sep 24, 2010 12:42 AM IST

Belgium based Helvoet Pharma, part of the Daetwyler Group is setting up its first greenfield production facility in Khandala Industrial Area, phase I (SEZ), on Pune- Bangalore Highway, near Pune. This is Helvoet Pharma s first plant in India. The company has invested Rs 120 crore for the plant.

The plant will manufacture components for primary packaging of parenteral pharmaceutical and diagnostic drugs and will produce four billion components at full capacity by end of 2014 and one billion in the first year. Products manufactured in Pune plant will be exported to US and other European markets.

With 100 employees, the plant will be operational by 2012, the new facility will cater to the needs of the local pharmaceutical industry and globally operating pharmaceutical customers in India and other markets.

Speaking on this Paul J. Haelg, CEO and head technical components, Daetwyler Group said, Helvoet Pharma s decision to build its own manufacturing plant in India has been made to leverage the country s position as the centre of excellence for generic and branded pharmaceutical products. India has the highest number of US FDA approved plants outside the USA and is expected to become a significant health care consumer market and has set a benchmark in this market.

Our confidence in the Indian market is reflected in our long association with the country and reflects the next step of our company s global business growth strategy. Our engagement dates back to 1991 when we started collaboration in India for distribution of our products, Guido Wallraff, head pharmaceutical packaging division, Daetwyler Group said.

Helvoet Pharma, a global supplier of primary and secondary pharmaceutical packaging components, was founded in 1970. The company is headquartered in Belgium and has additional manufacturing facilities located in Europe, the USA and Asia, supplying over 10 billion parts to the pharmaceutical industry every year.

Pharmaceutical marketing companies #pharmaceutical #rep

#pharmaceutical marketing companies


social media directory

Innovation, technology, the changing landscape of healthcare and marketing—if it’s worth mentioning, you can bet we’re talking about it. And we invite you to be part of that conversation.

To make it easier for you to find us in the social stream, we offer this handy directory of social spaces in which Intouch communicates, with an explanation of how we engage in each of them.

Whether you’re just getting to know us or if you’re an old friend who wants to stay connected, you’ll find us in these favorite social media hangouts:

Read our latest posts related to digital marketing and the healthcare industry from Intouch Solutions’ leaders and subject matter experts. We look forward to your comments.

Get highlights from our agency, the latest industry news and insights from our team. We also provide fun updates of what’s happening in our offices.

For prospective employees, we spotlight the latest career openings at Intouch, provide job hunt tips and give glimpses into our culture as well.

On our Facebook page, we provide updates from our agency, such as our involvement with healthcare causes or our latest award news. We hope you’ll “Like” it.

From our favorite vintage pharma ads to the latest creative work that caught our attention, our boards share informative infographics and creative inspiration.

Connect with us on LinkedIn to learn about the latest career openings, as well as updates on news that matters to us.

If you’re technology-minded like us, you could add us to your circles over at Google+ too. Our team loves to share news about the latest devices, search statistics and health innovations.

Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt #solvay #pharma

#hitech pharma


Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt Organizations (RICO) and Protein Spiking Allegations

ATLANTA. May 12, 2016 /PRNewswire/ — Protein supplement maker Hi-Tech Pharmaceuticals, Inc. says rival MusclePharm Corp. artificially inflates the level of protein in its Arnold Schwarzenegger Series Iron Mass product and then lies to consumers about it, violating federal competition and state consumer protection laws, according to a complaint filed in Georgia federal court. The lawsuit further alleges violations of the Racketeer Influenced and Corrupt Organizations (RICO) act and protein spiking allegations involving MusclePharm Sports Nutrition’s protein supplement.

This lawsuit comes days after Arnold Schwarzenegger terminated his relationship with MusclePharm due to years of his good name being dragged through the mud. The lawsuit alleges that MusclePharm and its former owner Brad Pyatt were engaged in a scheme to defraud consumers as to the Iron Mass product’s content, quality, characteristics, and/or ingredients, and caused and enabled consumers to purchase MusclePharm’s Iron Mass product instead of Hi-Tech’s NitroPro product.

The lawsuit’s allegations include that MusclePharm’s label makes misleading claims about its protein content. For example, the labeling claims that the product contains 40 grams of protein per serving; however, this figure allegedly also includes the amino acid, Glycine and; the non-amino acid compound, Creatine Monohydrate. According to the lawsuit, testing reveals that the actual content per serving of protein is 19.53 grams (48.5% of label claim) once protein-spiking agents are eliminated.

The lawsuit also alleges, “In furtherance of this scheme, MusclePharm used the Internet to disseminate its false product claims to consumers across the United States. and to enable consumers to purchase MusclePharm’s Iron Mass product online. It also used the U.S. Mail and/or other interstate carriers to ship Iron Mass to consumers throughout the United States in violation of 18 U.S.C. Section 1341. ” The suit further alleges, “Defendants have conspired to conduct and participate in the conduct of the affairs of the enterprise through a pattern of racketeering activity. That conduct constitutes conspiracy to violate Racketeer Influenced and Corrupt Organizations (RICO) 18 U.S.C. Section 1962(c), in violation of 18 U.S.C. Section 1962(d).” Passed the year after The Godfather was published, RICO is part of a 1970 law designed to allows plaintiffs to bring civil lawsuits against organizations whose members allegedly committed crimes.

Hi-Tech Pharmaceuticals lawsuit alleges that MusclePharm and Pyatt’s Iron Mass Protein does not contain the quantity of protein as claimed on the product’s label, and also alleges the use of non-protein ingredients in protein supplement products due to a process known as “protein-spiking.” These ingredients are added to increase a protein product’s nitrogen content while allowing the manufacturer to save on protein manufacturing costs. A popularly used protein content test uses nitrogen as a measure of protein; therefore, protein spiking serves to fool consumers into believing they are receiving more whey protein than is actually contained in the product.

About Hi-Tech Pharmaceuticals

Hi-Tech Pharmaceuticals ( ) is a leading Sports Nutrition manufacturer. Since 1979, Hi-Tech Pharmaceuticals, Inc. and its sister company, Hi-Tech Nutraceuticals, LLC. have been providing quality custom manufacturing services to the pharmaceutical, dietary supplement and beverage industries. Hi-Tech Pharmaceuticals is a cGMP certified company that operates out of Four (4) US Production facilities and (2) Warehouses, totally over 500,000 sq. ft. The two Georgia based production facilities are both located outside Atlanta in the Norcross and Suwanee Advanced Technology areas. Hi-Tech also has Two (2) facilities located outside State College, Pennsylvania. Hi-Tech holds a Drug Manufacturing License issued by the State of Pennsylvania Food and Drug Branch and is registered as a Food and Drug Establishment with the FDA in Pennsylvania .

Hi-Tech Pharmaceuticals is an enormously successful company that creates, manufactures and sells high-quality products sold by the large, major retailers across the United States. These retailers include: GNC, Vitamin Shoppe, Rite Aid, Kroger, Winn-Dixie, Albertson’s, CVS, Duane Reade. Hannaford, Cardinal Health, McKesson, Mclain, Harmon Stores. Fred Meyer. Osco Drugs, Supervalu, Roundy’s, Walgreens, Sav-On Drugs, Meijer, Fruth Pharmacy, Kinney Drug, Kinray, USA Drugs, A P, Kmart,,,, and over 5,000 independent drug stores, as well as in more than 80,000 convenience stores throughout the United States .

SOURCE Hi-Tech Pharmaceuticals, Inc.

Related Links

Hi-Tech Pharmaceuticals Files Lawsuit against MusclePharm over Racketeer Influenced and Corrupt Organizations (RICO) and Protein Spiking Allegations

Pharmaceuticals industry #ims #pharma

#pharmaceuticals industry


Pharmaceuticals industry

Belgium is a world leader in the pharmaceuticals industry. The latter is a key sector in terms of jobs: it employs almost 30,000 workers in Belgium and this figure is growing year on year. Pharmaceuticals account for over 10% of Belgium’s total exports.

Accordingly, both the pharmaceuticals industry and the Belgian government are investing heavily in developing this sector even further and major drives are under way to promote innovation and R D.

Private investment

Every year, the pharmaceuticals industry ploughs over €1.5 billion into R D. This represents 40% of all private investment in R D in Belgium, double the European average.

Government support

The government also supports the pharmaceuticals industry – and R D in general – via a range of tax incentives and discounts and by offering assistance in hiring qualified researchers. A consultation platform to forge links between the pharmaceuticals industry and the government has also been set up to improve public health and boost innovation and employment.

More info

Pharmaceutical Sales Interview #sun #pharma #news

#pharmaceutical sales industry

#’s exclusive practice interview with answers from the best selling Insider’s Guide to the World of Pharmaceutical Sales by Jane Williams. Review the description. A number of the underlined keywords have links to interview questions for that keyword or job function.

Description: Promote pharmaceutical drug sales by forging relationships with physicians, hospitals and managed care organizations. Through one-on-one sales presentations, group discussions and educational programs, a sales representative presents the latest in medical news and treatment programs.

Candidates require strong interpersonal skills. a team orientation and a mature, resilient outlook. Additional qualities include strong analytical and communications skills. Experience in the pharmaceutical industry and in advertising, marketing and sales, recent college graduates, and those with advanced business degrees are encouraged to apply.

Review these critical interview tips before your interview:

Search for current trends and subject areas for your Pharmaceutical Sales interview.

Practice Pharmaceutical Sales Interview

How did you decide pharmaceutical sales would be the right career for you?

This is the most basic of questions, but you are almost certain to be asked this question. While people interviewing for other types of positions are asked why they decided on their career choice, it is very important that you answer this question correctly for a pharmaceutical sales interview.

First tell them that you love selling and site examples where you have done this even if you haven�t been employed as a salesperson. Mention instances where you persuaded someone to “buy in” to your ideas, etc. That is selling! Mention that you have always been highly motivated, energetic, and enthusiastic. Successful sales people have all of these qualities as well as being creative and resourceful. Be prepared to cite examples where you displayed these behavioral characteristics.

Next, expound upon why pharmaceutical sales would be right for you. This is a good time to pull out the information that you have collected during your research. You can explain how stable the industry is, how exciting it would be to be part of such a dynamic field, and one where the opportunity to help thousands of people is a reality. State that this would give you tremendous job satisfaction. Also let them know that you realize the opportunities for personal and professional growth are tremendous with pharmaceutical sales companies. You will thrive on the daily challenges of performing a pharmaceutical sales representatives job. (This would be a great time to mention the “field preceptorship” and how much you enjoyed your day in the representative�s territory!) The research you have done on their company and the industry, and the extra effort you have put forth to spend a day in the field to see for yourself what a pharmaceutical sales representative does will give you tremendous credibility. You will be viewed as a serious candidate!

What is your current occupation?

Give an honest answer, but highlight any area of responsibility that you may have which would be seen as a benefit for someone in pharmaceutical sales. This would be a good time to show the “Career Comparison” information that you have placed in your Personal Presentation Binder. You will have already compared your job responsibilities to that of a pharmaceutical sales representative. Were you responsible for marketing a product or idea to others? Have you analyzed a “buyer” to determine that buyer�s potential? Do you have daily contact with physicians or other medical personnel in your day-to-day activities? These are excellent job responsibility areas to compare with pharmaceutical sales job responsibilities. Be careful not to make a negative statement. Always expect to be asked to prove any statement that you make!

I see you have held several different positions over the last five years? Can you explain why?

The obvious objective in this question is to determine whether you are a “job-hopper.” Training and educating pharmaceutical sales representatives is very time-consuming and expensive. A bad choice would yield an ineffective pharmaceutical sales representative and one that would potentially leave the job “undone” because that person has again decided to do something else. The district manager will attempt to ascertain whether you are a dependable person and whether you do indeed really want a career that offers upward mobility. He must be convinced that you will stay and work smart. If you have changed positions in order to increase the challenge of your job and allow upward mobility, then that is an excellent reason for changing jobs. Career transitions or job transitions made to increase compensation for your work is another good reason.

When did you decide to pursue a pharmaceutical sales career position?

You might reply that after your extensive research into this career field including actually going on a field preceptorship, that you believe this a perfect career for you. Then you must explain why it is perfect for you. It is perfect because you thrive on the type of challenges faced by pharmaceutical sales representatives! You want to make a difference at a job you are certain you will love. Pharmaceutical sales is a perfect match for your personality and work experience. Then supply proof for your statement.

How long having you been seeking employment in the pharmaceutical sales industry?

Your answer here will be important. You have the opportunity to make yourself look good with the right answer. If you have been looking for a position for a long time, six months or more, then you need to present yourself as a tenacious person who never gives up because you are absolutely certain that you are the right person for the job. Whether you have been granted interviews will matter, because the district manager will wonder why you didn�t gain the position if you interviewed. On the other hand, if you didn�t gain an interview that means you failed the first sales test. Perhaps you turned a position down because of location. That�s a good reason to decline. If you�ve just started looking for a pharmaceutical sales position and you�ve already gained interviews, it�s because you are impressive, on paper and in person.

How does your current or former job experience compare to pharmaceutical sales?

  • What was your rating on your last Performance Management Review?
  • How would you describe “selling?”
  • Name five reasons why you believe you would be a good pharmaceutical sales representative.
  • Have you interviewed with other companies?
  • How do you feel about working on your own most of the time?
  • Why should we hire you over other candidates?

  • Datwyler Pharma Packaging – New name, same passion for excellence – World Pharmaceutical Frontiers #e

    #helvoet pharma


    Datwyler Pharma Packaging – New name, same passion for excellence

    As part of its objective to reinforce its global competitive ability, Helvoet Pharma has changed its name to Datwyler Pharma Packaging, a division of the Datwyler Group, a Swiss company that is steeped in tradition and recognised worldwide. The former Helvoet Pharma customer base can be reassured that the name change will not have any detrimental impact on the actual manufacturing of goods. All products will continue to be made at the same sites and their quality will not be compromised.

    As well as the name change, Helvoet Pharma has undergone major developments. Construction of its manufacturing plant in India is progressing according to plan, with the start-up operation scheduled for 2012. As part of an ongoing reinforcement of its presence in Asia, the company is reviewing alternatives to increase its manufacturing footprint throughout the continent.

    This new phase of international expansion made it the ideal time to adopt the more globally applicable name of Datwyler Pharma Packaging, with a new, modern design. Doing so has tied Helvoet Pharma even more closely to the Dätwyler Group and increased its business activities under the unifying brand name. As a partner, customers will benefit from the increased stability and synergies, as well as from the innovative and financial power of a strong group, which achieved a 1bn turnover and employs 5,000 staff.

    Datwyler’s global quality management system meets the criteria of the strictest international standards, guaranteeing the highest confidence levels when it comes to product integrity and patient safety. The group’s global customer and process-orientated quality management system is based on the strict global guidelines of ISO 9001 and of current Good Manufacturing Practices.

    As such, it is well adapted to the manufacture of primary and secondary packaging materials for the most advanced domains of the parenteral pharmaceuticals market. Datwyler’s Pregnana production facility recently obtained the ISO 15387 certificate.

    Passion for excellence

    The Datwyler Group’s pharma packaging division is a leading supplier of primary and secondary packaging components (mainly rubber and aluminium) in the most advanced areas of the parenteral pharmaceutical market, with a specific focus on vaccines, diabetic care and biotechnology. Datwyler was founded in 1970 and is the world’s number two in the parenteral pharmaceutical packaging market. The company is headquartered in Europe, with additional manufacturing facilities located throughout Europe, US and Asia, serving 14 billion parts every year to the industry.

    For over four decades, the company has continued to build its reputation for reliability, high-quality products and customer support. As Datwyler, the company will continue the journey that Helvoet Pharma began. The name, brand and logo may be changing, but the promise to customers remains the same: a passion for excellence. Datwyler would like to thank its clients for their excellent cooperation and looks forward to continuing to supply high-quality pharmaceutical packing components and industry-leading services in order to optimise worldwide market success.

    Products and Services

    Contact Details

    Senator calls for investigation of Purdue Pharma following Times story on OxyContin – LA Times

    #purdue pharmaceuticals


    Senator calls for investigation of Purdue Pharma following Times story on OxyContin

    A U.S. senator on Friday called for federal investigations of OxyContin s manufacturer in response to a Los Angeles Times report that found the bestselling painkiller wears off early in many patients, exposing them to increased risk of addiction.

    Sen. Edward J. Markey, a Massachusetts Democrat whose state has been hit hard by prescription drug abuse, urged the Justice Department. the Food and Drug Administration and the Federal Trade Commission to launch probes of drugmaker Purdue Pharma.

    OxyContin s main selling point is that it lasts 12 hours. The Times investigation published this month found that when the effects don t last, patients can suffer symptoms of narcotic withdrawal, including intense craving for the drug, and experience a cycle of agony and relief that experts say promotes addiction.

    OxyContin is the original sin of the current opioid epidemic. Sen. Edward J. Markey

    The newspaper found that Purdue had evidence of the problem for more than two decades, but continued to insist the drug lasted 12 hours, in part, to protect its revenue. OxyContin s market dominance and premium price hinge on its 12-hour duration. Purdue instructed doctors who complained about the drug s duration to prescribe stronger, but not more frequent, doses. Research shows that patients taking high doses of opioids are at greater risk of an overdose and death.

    ‘You want a description of hell?’ OxyContin’s 12-hour problem

    Harriet Ryan, Lisa Girion and Scott Glover

    Harriet Ryan, Lisa Girion and Scott Glover

    These are serious allegations, Markey wrote of The Times findings in a letter to Atty. Gen. Loretta Lynch. They raise questions about ongoing deception by Purdue, harm to the public, continued costs to the United States, and the availability of further judicial recourse against Purdue

    In a separate letter to the heads of the FDA and FTC, Markey called OxyContin a leading culprit in the current opioid and heroin overdose epidemic. More than 194,000 people have died from overdoses involving opioid painkillers since 1999 and abuse of those drugs is blamed for the resurgence in heroin addiction in the U.S. Markey said the agencies should proactively warn prescribers, patients, and the general public about problems the newspaper identified with OxyContin.

    Purdue, a family-owned Connecticut company that has collected more than $31 billion from OxyContin sales, rejected The Times findings. In a statement, the company said Purdue shared Markey s concerns about the opioid epidemic, but noted that the FDA approved OxyContin as a 12-hour drug.

    We promote our medicines only within the parameters approved by FDA and, given FDA has not approved OxyContin for eight-hour use, we do not recommend that dosing to prescribers, the statement said.

    A Justice Department spokesman said the department was reviewing the letter and an FTC spokesman confirmed the agency had received the letter, but declined comment.

    An FDA spokeswoman said the agency was reviewing the letter and would respond directly to Markey. Previously, the agency spokeswoman told The Times the FDA will revise labeling as necessary to improve proper prescribing and treatment, but also placed responsibility with doctors.

    It should be well understood by physicians that there will be some individual variability in the length of time that patients respond to this drug, the spokeswoman said.

    Dr. Lewis Nelson, a New York University professor of emergency medicine who has advised the FDA on risks of prescription opioids, said that in his experience teaching physicians around the nation, many doctors have forgotten their medical school training about how opioids work in individuals.

    I don t think the average doctor would recall the difference between changing a dose to q8, medical shorthand for every 8 hours, or increasing the dose, Nelson said.

    He said the Times findings were credible and the FDA should change the label.

    It would seem like this is a very fixable problem, Nelson said.

    OxyContin s history is inextricably linked with the prescription drug epidemic. Purdue launched the drug in 1996 with an aggressive marketing campaign to primary care doctors that presented the painkiller as appropriate treatment for back aches and knee pain. Purdue and three company executives pleaded guilty in 2007 to federal charges of drug misbranding for what the company acknowledged was an attempt to downplay OxyContin s risk of addiction. They were ordered to pay $635 million.

    Markey has been an outspoken critic of the role of pharmaceutical companies and the FDA in the opioid crisis. In January, he temporarily blocked the nomination of Dr. Robert Califf as FDA commissioner to protest the agency s approval process for opioids, including its August decision to approve OxyContin for use in children as young as 11. Califf was later confirmed.

    OxyContin is the original sin of the current opioid epidemic, Markey said in a statement to The Times. For years, Purdue Pharma lied to federal regulators and the public about the addictiveness of OxyContin and countless patients got hooked on this deadly painkiller. We need to know if Purdue once again lied about the longevity of OxyContin s pain-relieving properties and hold Purdue accountable.

    Markey s focus on opioids reflects Massachusetts severe problem with painkillers and heroin, which has been embraced by many prescription drug addicts as a cheaper alternative to pills. The death rate from opioid overdoses is more than twice the national average and climbing. More than 1,300 people died from opioid-related causes last year, according to the Massachusetts Department of Public Health.

    Four people die every day and we haven t been able to bend the trend, said Marylou Sudders, the commonwealth s secretary of health and human services. That s not a problem. That is a crisis.

    Sudders attributed the problem, in part, to doctors over-prescribing opioids. A state law passed in March requires doctors to receive additional training and limits first-time opioid prescriptions to seven days.

    The Times report concerned an issue that went largely unnoticed in the scrutiny of OxyContin: the drug s duration. Purdue s clinical trials demonstrated the problem. In the first test on patients, for example, OxyContin wore off early in about half of participants.

    After the drug hit the market, the company was confronted with additional evidence, including complaints from doctors and research by outside scientists.

    In his letter to Lynch, Markey wrote that if warranted the Justice Department should try to recoup taxpayer dollars that federal healthcare programs may have needlessly and unnecessarily spent on OxyContin prescriptions.

    12:52 p.m.: This post has been updated to include statements from the FTC and statistics about opioid deaths in the U.S.

    10:33 a.m.: This post has been updated to include statements from Purdue.

    9:46 a.m.: This post was updated to include responses from the Justice Department and the FDA.

    This article was originally published at 7:10 a.m.

    Astellas Pharma South East Europe #pharma #logos

    #astellas pharma



    We strive to be best-in-class in therapeutic areas where there is a vital need for treatments that improve and lengthen patients’ lives. Treatments that offer patients and their doctors genuinely new options for improving care.

    Astellas Pharma South East Europe is improving the future of patients in five key therapeutic areas


    Innovative therapies in preventing organ rejection after transplantation


    World-leading approach in R D to satisfy unmet patient needs in urological conditions


    Our commitment is to developing first-in-class and best-in-class therapies


    Addressing the complex challenges of serious fungal and bacterial infections

    Pain Management

    Pioneering treatments that effectively manage chronic pain

    UCB to buy Schwarz Pharma for $5 #market #research #companies

    #schwarz pharma


    UCB to buy Schwarz Pharma for $5.6 billion

    LONDON (MarketWatch) — Belgium’s UCB on Monday said it agreed to pay $5.6 billion for Germany’s Schwarz Pharma, the third multibillion-dollar takeover in the European pharmaceutical industry in the past five days.

    UCB (000373953) said it’s paying 4.4 billion euros in cash and shares, representing a 20% premium to Friday’s close, for Schwarz Pharma (722190).

    The deal follows proposals by Germany’s Merck KGaA (659990) to buy Switzerland’s Serono SRA, +0.00% for $13.3 billion, and Denmark’s Nycomed to buy the pharmaceutical operations of Germany’s Altana AAA, +8.70% for $5.8 billion.

    Those deals had driven up Schwarz Pharma’s price, as UCB is offering 28% more than the German company’s value before the Serono and Altana deals.

    Roch Doliveux, chief executive of UCB, denied that the recent deals prompted the companies to act.

    I think the recent consolidation may have started a few weeks ago, whereas we have certainly known each for quite a while and have been discussing for many, many months, he said.

    UCB is offering 50 euros cash plus 0.8735 share for each Schwarz Pharma share. The proposal values Schwarz Pharma at 91.1 euros based on Friday’s closing prices.

    All the shares UCB is paying to Schwarz Pharma will come from a capital increase.

    The controlling Schwarz family has pledged to vote its 60% holding in support of the deal and to hold UCB shares through June 2010.

    Schwarz Pharma’s shares jumped 19.9% to 90.68 euros. Shares of UCB, after initial losses, rose 2% to 48 euros. Read Europe markets.

    Neurology strength

    The combined companies would have annual revenue of more than 3.3 billion euros, global leadership in neurology and a more diversified product portfolio, the companies said.

    Credit Suisse analyst Ravi Mehrortra said the neurology expertise of UCB’s sales force could bolster sales of Schwarz Pharma’s lacosamid, currently in development as a therapy against epilepsy and naturopathic pain.

    This could turn lacosamide from a product with peaks sales of around 700 million euros to a $1.5 billion product, in our opinion, he said.

    Part of Schwarz Pharma’s portfolio also includes a license to Pfizer Inc. PFE, +0.26% to make a bladder-control drug.

    The companies expect more than 300 million euros a year in synergies after three years, and they anticipate the deal will lift adjusted earnings in the second year.

    UCB will still be headquartered in Brussels, while the Schwarz Pharma name will be used to headquarter the primary-care business.

    Schwarz will still be operated from Monheim, Germany.

    Braveheart Financial Services and Lazard advised UCB. Rothschild advised Schwarz Pharma.

    Copyright 2016 MarketWatch, Inc. All rights reserved.

    Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.





    No results found


    Barr Pharma Ex-CEO Takes On VC – Venture Capital Dispatch #akela #pharma

    #barr pharma


    Barr Pharma Ex-CEO Takes On VC

    Mar 13, 2009 10:38 am ET

    Here s some venture-capital matchmaking at its finest.

    When Barr Pharmaceuticals Inc. was acquired by Teva Pharmaceutical Industries Ltd. in December, Barr s chief executive, Bruce Downey, found himself without a job. Meanwhile, venture capital firm NewSpring Capital was prepping to raise a new, bigger health care fund and needed a third partner.

    Neither of them had to look very far. For the past four or five years, Barr had served as a limited partner in two earlier NewSpring funds the only VC firm it had invested in and Downey had worked on the firm s advisory committee for several years. He even had participated in the evaluation of several of NewSpring s investments, he said.

    So it was natural for Downey to begin talking with NewSpring about a new career move. NewSpring partners found their match and on April 1, Downey will become a venture capitalist. “I didn t think about that at all, but I really respect what they do here, Downey said. The reason I came here is I respect the quality of the people, the quality of the organization.

    Downey had served as president of Barr Pharmaceuticals since 1994 and became CEO a year later. Under his leadership, the Montvale, N.J.-based generic drug maker’s revenue rose from $60 million to $2.5 billion last year.

    Despite the fundamental differences between chief executives and venture capitalists, Downey said he thought the transition would not be difficult. “We all do a similar thing, looking to grow companies,” he said, adding that he’d been involved in hunting for acquisition targets while heading Barr.

    He joins Radnor, Pa.-based NewSpring as the firm is in the midst of raising a $150 million second health care fund. The fund already held a $65 million first close last January, and it will be significantly larger than Commerce Health Ventures LP, NewSpring s first dedicated life science fund that closed in 2005 with $36 million.

    Besides the life science business, NewSpring also closed a $165 million fund early last year for business services, enabling technology and information technology. Veronica Rosa, director of communications at the firm, said it will shortly begin raising a second mezzanine fund, although she declined to provide details on the fund.

    Promentis Pharmaceuticals, Inc #pharmaceutical #jobs

    #schwarz pharma


    Chad Beyer is President CEO of Promentis. He has nearly 20 years of experience in the research, discovery and business development of medications aimed to treat CNS and neurological disorders. Prior to joining Promentis, Dr. Beyer served as the Head of Neurochemistry and led the Psychiatry Task Force at Wyeth Pharmaceuticals in Princeton, NJ. During his career at Wyeth, Dr. Beyer led several early-stage drug discovery teams and managed a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has authored more than 70 manuscripts, 3 patents, co-edited Next Generation Antidepressants and is co-founder of the journal Technology Transfer Entrepreneurship. Dr. Beyer is also an adjunct faculty member at Thomas Jefferson University in Philadelphia where he teaches Bioventure Management , a class focused on the business of doing science.

    Daniel Lawton is the current Chairman of the Board and former CEO of Promentis Pharmaceuticals. Mr. Lawton has more than 20 years of experience in the pharmaceutical and life sciences industry. Previously, Mr. Lawton was Group President at Dohmen Life Sciences, and Vice President and General Counsel of Schwarz Pharma, Inc. where he was also a member of the US senior management group. His previous work experience includes a number of senior positions at Abbott Laboratories supporting its US, Canadian, European and Japanese businesses, with a focus on new business development, licensing, acquisitions and related transactions. Mr. Lawton has practiced law at firms in Europe and the United States. He is a graduate of Harvard Law School and was a Teaching Fellow at Harvard University (Economics under Professor Martin Feldstein).

    Dr. Veitinger is currently a Venture Partner with OrbiMed and a current Promentis Board member. He previously served as Chairman of Promentis Pharmaceuticals from April 2008 until February 2014. During his prior 16-year pharmaceutical career, Dr. Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M A, as well as general management. Most recently Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Dr. Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Dr. Veitinger received his medical degree and his doctorate (Ph.D.) from the University of Heidelberg. He earned his M.B.A. at INSEAD in France.

    Patrick Schwarz-Schuette began serving on Promentis Board in 2009. Mr. Schwarz-Schuette is currently the Managing Director of Black Horse Investments GmbH in Dusseldorf, Germany. Previously, he led Schwarz Pharma AG as Chairman of its Executive Board for more than a decade (1992 to 2006), culminating in the sale of the Schwarz group to UCB in a transaction valued at approximately six billion US Dollars. Before assuming the role of Chairman, Mr. Schwarz-Schuette was a member of the Schwarz Pharma Executive Board (1988 to 1992), and previously led Sanol GmbH as General Manager. Early in his career, Mr. Schwarz-Schuette was a Management Consultant at Booz Allen Hamilton, and received his diploma in business administration from the University of Hamburg.

    David Baker cofounded Promentis Pharmaceuticals in 2007, currently serves as a Director and chairs the Scientific Advisory Board. Dr. Baker is also Professor and Associate Chair in the Department of Biomedical Sciences at Marquette University. He previously served as a postdoctoral fellow at the Medical University of South Carolina in the laboratory of Peter Kalivas. Dr. Baker earned his Ph.D. at Arizona State University in 1999 and his B.S. at Montana State University in 1992 working in the laboratories of Dr. Janet Neisewander and Dr. Michael Babcock, respectively. He has had an active research career examining the neurobiological basis of diseases of the brain. Since 2001, his research has focused on identifying novel therapeutic targets capable of normalizing brain circuitry that underlies compulsive disorders. During this time, Dr. Baker pioneered research implicating system xc- as a key component of pathological glutamate signaling; work that served as the scientific basis for Promentis Pharmaceuticals. His achievements have been featured in the Marquette Magazine cover story (Winter 2009 issue)“Searching for a Cure for the Brain’s Darkest Diseases” and earned him the 2010 Daniel X. Freedman Award from NARSAD for outstanding basic research achievement. In addition, he has been the recipient of the Milwaukee Health Care Award in 2012 and The Business Journal’s Forty under 40 Award in 2010, honoring Milwaukee’s up-and-coming leaders.

    Edward Barthell is a current Board member of Promentis Pharmaceuticals and has acted as an advisor to Promentis since the company’s incorporation in 2007. Dr. Barthell is currently CEO of EmOpti, Inc. a company supplying advanced analytics, command center and telemedicine technology to improve performance across the spectrum of acute care. He previously served as Vice President and Medial Director Americas for Caradigm, a 50:50 joint venture of Microsoft and GE Healthcare, and before that as Director for Connected Health for Microsoft’s Health Solutions Group. Dr. Barthell was co-founder and Chief Medical Officer of EMSystem, a provider of networking software in emergency medicine, and he was founder and President of the National Institute for Medical Informatics, the sponsor of the Wisconsin Health Information Exchange (WHIE). Dr. Barthell was the executive vice president and CIO for Infinity HealthCare Inc. a 130+ physician group practice emphasizing emergency medicine. He practiced as a board certified emergency physician for over 20 years in Wisconsin and earned his medical degree at the University of Wisconsin at Madison.

    Virinder Nohria is a member of Promentis Board. Dr. Nohria is also a board-certified neurologist with a special qualification in child neurology. He co-founded Vidara Therapeutics (2011) and served as its President and Chief Medical Officer until its sale to Horizon Pharma in 2014. Previously, Dr. Nohria was part of the founding team of Alaven Pharmaceutical LLC and Alaven Consumer Health LLC where he served as Chief Medical Officer, Chief Compliance Officer and Executive Vice President from 2008 until its sale to Meda Pharma (2010). Additionally, Dr. Nohria worked for Eli Lilly on Zyprexa® and at UCB, where he was clinical lead for submission and commercialization of Keppra® in the United States. He has also held the positions of Vice President and Chief Medical Officer at Xcel Pharmaceuticals where he led development of retigabine for the treatment of epilepsy. In addition to Promentis, Dr. Nohria currently sits on the board of directors of Horizon Pharma plc, and Sebela Pharmaceuticals. Dr. Nohria s earned his medical degree from the University of Cambridge in England and his Ph.D. in Neuropharmacology at the University of Leeds.

    The Future of Pharma: Innovation #pharmaceutical #suppliers

    #future of pharmaceutical industry


    Understanding what is meant by “innovation” and how it is measured is a critical step as we look towards meeting unmet healthcare needs.

    Pharmaceutical and biotech leaders will join IDEA Pharma in launching the first in a series of panel discussion sessions, called “The Future of Pharma”. on the evening of January 11th 2016, at the time of the annual J. P. Morgan Healthcare Conference, San Francisco.

    IDEA Pharma CEO Mike Rea has 20 years’ experience in global pharma strategy and is acknowledged as the leading expert in early-phase Positioning and Value Proposition for the pharma industry. “The idea behind ‘The Future of Pharma’ panel sessions,” explains Rea, “is to collect the most influential pharma leaders and hear their thinking about how we can positively shape the future of our industry, in addition to promoting healthier values and ethical practices.”

    The January panel discussion on the multi-dimensional topic of innovation within the industry will see IDEA Pharma joined by a panel of esteemed industry professionals – David Meek, Baxalta’s Executive Vice President and President of Oncology; Dr William Hait, Janssen’s Global Head of R D; Bob Oliver, Otsuka America Pharmaceutical Inc.’s President and COO; and, Dr Michael Hayden, Teva’s President of Global R D and Chief Scientific Officer. “I am delighted to welcome such influential industry players to the panel,” says Rea.

    “Innovation is the first topic up for discussion because it sits firmly at the top of everyone’s agenda, yet its definition and focus varies greatly company-to-company,” explains Rea. “Innovation is an area where companies are struggling to understand ‘best practice’ and, therefore, to emulate or improve upon their performance. Understanding what is meant by ‘innovation’ and how it is measured is a critical step as we look towards solving unmet healthcare needs, and having health policy makers and practitioners recognize and give priority to true pharmaceutical innovations.”

    “At the core of our belief is that innovation is not the same as invention: we look very objectively at the outcome, to see whether companies are launching their ‘innovations’ successfully,” Rea adds, clarifying that, “Although that sounds simple, it is a very good test for whether they are all talk or whether they are able to bring game-changing medicines to market. Launching innovation is a much higher order competence than coming up with ideas.”

    Defining the evaluation process

    At the panel discussion, IDEA Pharma, which has been heralded as a champion of innovation and industry change, will announce the launch date of its sixth annual Productive Innovation Index (PII). an index that ranks the top 30 pharmaceutical companies in terms of their ability to develop and commercialize innovations. At the same event, IDEA Pharma will also be unveiling the IDEA Index; this index is aimed at rewarding the most innovative companies selected from companies in the field of both pharma and biotech.

    Rea describes the PII, saying, “The Productive Innovation Index doesn’t apply a forward view; if it did, we’d be guessing like everyone else. It takes a rolling window of the past 5 years, so essentially it tells you who has been the most innovative of the top 30 companies in the past 3-5 years. This makes the ranking both easier and more robust in its objective.”

    Companies that don’t fall within the top 30 won’t be left out. In recognition of the fact that a huge amount of innovation is being brought into the top 30, IDEA Pharma felt that newer companies, which often react to change quickly, needed a different set of criteria for the new index. Rea explains, “The IDEA Index was created because there are clearly some very interesting things happening both outside the top 30 companies by revenue and within those companies where innovation is happening outside of NCEs (New Chemical Entities).”

    Our belief is that if a company comes up with a product that meaningfully impacts patient needs and is highly differentiated in doing so, that provides its own commercial model. The challenge is often that most businesses that say they are patient-centric are not, or they don’t really know what that means, so they are stuck between two ideologies, being neither one thing nor another.

    Rea acknowledges that the new index’s rankings will be more subjective because they are “based on applying a snapshot judgment of 2015/2016 activities across the whole industry for where innovation is bringing us game-changing medicines. As we have spent so much time studying how innovation gets to market in pharma, we believe the IDEA Index will recognize some remarkable companies, who will certainly be making a difference in the next 5 years.”

    What if an innovative idea is a bad one?

    “That’s an interesting question, says Rea, adding, “Ideas are often not intrinsically bad – it may be a factor of their context or their environment – because in a different area they may succeed. However, the focus of our indices is to reward excellence, not to punish any laggards.” In the role of the path-to-market function of IDEA Pharma, it would then be a case of encouraging the company to come up with a better solution, as well as working through the various scenarios until they arrive at a winning formula.

    Gaining the best outcomes for good products

    Having developed a great product, the next step is in marketing it successfully – and that isn’t as simple as it sounds. “Our belief is that the product is only the start of a journey; the path it takes to market is a very rocky road. There are so many choices including patient population, indication, label claims, dose, comparators, and value propositions that are all a part of the planning that produces successful products. Many ‘good products’ don’t make it to market or to patients, because of decisions taken in the path to market design,” says Rea.

    Molding products to patient needs

    There is something of a dichotomy within pharma: patient-centric focus is at the core of business, but so is producing a commercially successful product. Molding the two takes some skill, something like blending two colors until one is indistinguishable from the other yet in the process producing a clear new color, of greater value than the two original colors.

    “It is rare in our business that a product that is truly patient-centric is not also successful”.

    Rea says, “Our belief is that if a company comes up with a product that meaningfully impacts patient needs and is highly differentiated in doing so, that provides its own commercial model. The challenge is often that most businesses that say they are patient-centric are not, or they don’t really know what that means, so they are stuck between two ideologies, being neither one thing nor another.”

    He adds, “It is rare in our business that a product that is truly patient-centric is not also successful.” Various leaders have reiterated what Rea has said in regard to patient-centricity. The central message coming from the likes of Jill Donahue (Engage Rx), Jane Griffiths (Company Group Chairman, Janssen Pharmaceuticals), and Anne Beal (Chief Patient Officer at Sanofi) is that if you find a solution that works for your patients, the revenue will follow.

    Breaking down silos

    Over decades, siloed thinking became part of pharma and breaking down those barriers is a challenge – particularly in large companies where departments have been used to a certain way of doing things. Rea agrees: “I think it is a change that is happening, slowly, in some. Those companies towards the top of the PII tend to show better behaviors in this regard. However, some of the best proponents of innovation are not in large pharma. Smaller companies or teams don’t have the same barriers to cooperation.”

    Practicing effective altruism

    While a number of companies are doing impressive work in less developed countries and in neglected diseases, Rea admits that although global health initiatives aren’t really his area of expertise he does feel that the focus should be more on enhancing innovation. “At a philosophical level, I’d like to see pharma companies get better at what they do, which is already a significant benefit to society – like the effective altruism movement, just being a ‘good’ pharma company would improve global health. There is a risk that real, meaningful initiatives are hidden among the PR exercises.”

    Sexy Science not a benchmark for innovation

    Rea concludes, “We have written a lot about innovation news coverage being too focused on the discovery phase of pharma. One thing that PII implicitly recognizes is that innovation through the whole chain, into development, commercialization – including manufacturing and integration with healthcare systems – are all meaningful.” News reports tend to focus on the “aha” moment when scientists find a breakthrough. “We risk being dragged into ‘sexy science’ as the only benchmark for innovation, and that is clearly not enough. No medicine is less useful than one that does not make it to patients,” he says.

    The panel discussion in January promises to be one that will provide insights into how industry leaders work with their teams in bringing innovative ideas to the marketplace successfully, always keeping the patient uppermost in mind.

    What are the top job boards in the pharmaceutical #french #pharmaceutical #companies

    #biotech pharma jobs


    What are the top job boards in the pharmaceutical/biotech space?

    Great question – In my opinion one of the best tools there is when looking for a job in the pharmaceutical/biotech space is Linkedin.

    Creating a profile on Linkedin is essentially your chance to showcase your strengths, thus encouraging not only the right people, but also the right opportunities to come to you.

    Here are a few tips to help you create a great Linkedin profile:

    1. Upload a picture: Make this a professional headshot – nothing inappropriate!

    2. Summary: Write this in the mindset of a prospective employer. It might be best to write this in Microsoft Word first so that you can easily cut, paste and edit – this might also help you to organize your thoughts. When writing the summary it might be useful for you to keep in mind the following: If someone were introducing you to another person, what would you want this person to know about you and why? Mention the following:

    · Who are you currently? What company do you work for and what makes them special?

    · What have you accomplished? Pick 3-5 things – they can be regarding jobs, education, and honours.

    · Goals that you would like to achieve in the future.

    · In the specialties section, list any trade or skill which you think you have learnt with some ability.

    3. Descriptions about past jobs: This will help viewers understand where you come from in more depth than your summary will.

    · Treat this as your online CV – the easiest way to complete this section is to cut and paste sections of your CV, to ensure it includes a good number of keywords.

    · Use bullet points.

    · Include any contract work, non-profit assignments, or any other work experience.

    4. Education: Start at Secondary and Undergraduate education. You can also list vocational education or any courses you have attended.

    5. Have more than 30 contacts: This shows viewers of your profile that you are professional and that you know how to network. Also, by increasing the number of people you are connected to, you increase the likelihood of people viewing your profile.

    6. Recommendations: Sometimes, what other people write about you is more valuable that what you write about yourself. A good way to get recommendations is to recommend other people. Recommendations don’t necessarily have to come from people who work above you.

    7. Customise your URL: This will help your profile rank higher on Google and make it easier for people to find you. Your LinkedIn URL should appear as “ ourfullname .” To do this, go to your profile and click “edit” and then next to where it says “public profile,” click “edit” again. At the top, you’ll want to click “edit” one more time next to “your public profile URL,” and then type in your full name, without spacing, and click “set address.” If the unique URL is taken, then try using a period between your first and last name or use your middle initial.

    · Make sure your profile is completely grammatically correct and that each section is complete.

    · Flood your profile with lots of keywords relevant to the pharma industry you work in.

    · Frequently update your status with useful content, where possible including a link back to the company website.

    · Actively comment on Linked In discussion forums – this gives you the opportunity to demonstrate your skills and knowledge of relevant industries. These discussion forums are essentially a 24/7 networking event.

    I hope you have found this useful. o)

    Herb Pharm Pharma Kava 1 oz #pharma #management

    #pharma kava



    Promotes Peaceful Relaxation. Reduces Stress Frustration.

    40-drop dose contains 64 mg of kavalactones. Pharma Kava is prepared from the rhizome roots of Piper methysticum plants which are naturally grown in the South Pacific islands of Vanuatu.

    Caution: US FDA advises that a potential risk of rare but severe liver injury may be associated with kava-containing dietary supplements. Ask a healthcare professional before use if you have or have had liver problems frequently use alcoholic beverages or are taking any medication. Stop use and see a doctor if you develop symptoms that may signal liver problems including jaundice (yellowing of the skin or whites of the eyes) and brown urine. Other nonspecific symptoms can include nausea vomiting light-colored stools unexplained tiredness weakness stomach or abdominal pain and loss of appetite. Not for use by persons under 18 years of age or by pregnant or breastfeeding women. Not for use with alcoholic beverages. Excessive use or use with products that cause drowsiness may impair your ability to operate a vehicle or heavy equipment. Use only as directed label.

    Two or three times per day take 40 drops in a little water.

    Supplement Facts

    Directions for Use: Two or three times per day take 40 drops in a little water.

    Other Directions: FDA advises that a potential risk of rare but severe liver injury may be associated with kava. Ask a healthcare professional before use if you have or have had liver problems frequently use alcoholic beverages or are taking any medication. Stop use and see a doctor if liver symptoms occur (unusual fatigue abdominal pain appetite loss dark urine pale stools yellow eyes or skin). Not for use by persons under 18 years of age or by pregnant or breastfeeding women. Do not take with alcoholic beverages. Excessive use may briefly impair ability to drive or operate machinery. Keep out of the reach of children.

    Other Ingredients
    Contains certified organic grain alcohol (83-93%) & Kava extractives.

    Contains certified organic grain alcohol (83-93%) & Kava extractives.

    Sankyo pharma #pharma #consulting #companies

    #sankyo pharma



    Daiichi Sankyo Co. Ltd
    3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo
    103-8426 Japan

    Your access to this site has been limited #pharma #logos

    #spi pharma


    Your access to this site has been limited

    Your access to this service has been temporarily limited. Please try again in a few minutes. (HTTP response code 503)

    Reason: Access from your area has been temporarily limited for security reasons

    Important note for site admins: If you are the administrator of this website note that your access has been limited because you broke one of the Wordfence firewall rules. The reason your access was limited is: “Access from your area has been temporarily limited for security reasons”.

    If this is a false positive, meaning that your access to your own site has been limited incorrectly, then you will need to regain access to your site, go to the Wordfence “options” page, go to the section for Rate Limiting Rules and disable the rule that caused you to be blocked. For example, if you were blocked because it was detected that you are a fake Google crawler, then disable the rule that blocks fake google crawlers. Or if you were blocked because you were accessing your site too quickly, then increase the number of accesses allowed per minute.

    If you’re still having trouble, then simply disable the Wordfence firewall and you will still benefit from the other security features that Wordfence provides.

    If you are a site administrator and have been accidentally locked out, please enter your email in the box below and click “Send”. If the email address you enter belongs to a known site administrator or someone set to receive Wordfence alerts, we will send you an email to help you regain access. Please read this FAQ entry if this does not work.

    This response was generated by Wordfence.